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Abstract 
Keywords: Aptamers, flow cytometry, aptamer-quantum dot conjugates, 
diagnostics, cell line development, screening 
 
The overageing population in countries of the western world presents huge challenges 
for the society. An enourmous pressure thereby lies on the health care system, which 
has to take care of a constantly increasing number of people in need for treatment due to 
the demographic change. In the future, the health care system will hence have to 
provide treatments for more patients with more complex and costly diseases. The 
resulting cost pressure is already affecting companies operating in the health care 
environment and will increase further. Suppliers of diagnostic tests and the 
pharmaceutical industry therefore have to try to produce new, innovative and above all 
cost-saving products to stay competitive in the market. 
Through the use of certain innovative chemical reagents, called aptamers, it could be 
possible to develop cost-saving applications for diagnostics and more efficient 
processes for the manufacturing of drugs. This work points out two potential application 
areas for aptamers in these fields and explores the feasibility of the applications. In the 
first part of the work the use of aptamers as detection probes in flow cytometry is 
shown. Flow cytometry has a high clinical relevance and is used routinely for analysis 
of patient samples to screen for tumor cells. It could be demonstrated that aptamers can 
be used to specifically label certain cell surface molecules. In addition, the fabrication 
and characterisation of functional aptamer quantum dot conjugates is described. These 
probes are promising tools for future applications of aptamers in flow cytometry. The 
second part of the work investigates the use of aptamers for optimisation of 
biotechnological production processes. Many newly developed drugs are produced by 
processes that use cultured cells. A flow cytometry based screening could help to find 
the most productive cells in a population and thereby help to manufacture drugs more 




Schlagwörter: Aptamere, Durchflusszytometrie, Aptamer-quantum dot 
Konjugate, Diagnostik, Zell-Linien Entwicklung, Screening 
 
Die alternde Bevölkerung in den Ländern der westlichen Welt stellt die Gesellschaft vor 
große Herausforderungen. Sehr hoher Druck lastet dabei auf dem Gesundheitssystem, 
das durch den demografischen Wandel eine immer größere Anzahl kranker und 
behandlungsbedürftiger Menschen versorgen muss. Das Gesundheitssystem wird 
folglich in Zukunft mehr Menschen mit komplexeren und kostenintensiveren 
Krankheiten bei einem sinkenden Anteil an Beitragszahlern versorgen müssen. Der 
entstehende Kostendruck wirkt sich bereits jetzt auf die im Umfeld des 
Gesundheitssystems agierenden Unternehmen aus und wird weiter zunehmen. Hersteller 
diagnostischer Tests und die Pharmaindustrie müssen daher versuchen neue, innovative 
und vor allem kostengünstigere Produkte herzustellen, um weiter am Markt bestehen zu 
können.  
Durch den Einsatz von innovativen chemischen Reagenzien, sogenannten Aptameren, 
könnten neue, kostengünstigere Anwendungen für die Diagnostik entwickelt werden 
und Produktionsprozesse für Medikamente effizienter gestaltet werden. Diese Arbeit 
zeigt zwei mögliche Einsatzbereiche für Aptamere und erforscht ihre Machbarkeit. Im 
ersten Teil der Arbeit wird der Einsatz von Aptameren als Detektionsmoleküle in der 
Durchflusszytometrie gezeigt. Die Durchflusszytometrie besitzt eine hohe klinische 
Relevanz und wird routinemäßig für die Analyse von Patientenproben auf Krebszellen 
verwendet. Die Arbeit zeigt den Einsatz von Aptameren zur spezifischen Färbung 
bestimmter Zelloberflächenmoleküle. Darüber hinaus wird die Herstellung und 
Charakterisierung funktioneller Aptamer Quantum Dot Konjugate beschrieben. Diese 
Reagenzien sind vielversprechende Werkzeuge für zukünftige Anwendungen von 
Aptameren in der Durchflusszytometrie. Im zweiten Teil der Arbeit wird der Einsatz 
von Aptameren für die Optimierung von biotechnologischen Produktionsprozessen 
erforscht. Viele der neu entwickelten Medikamente werden mit Hilfe von kultivierten 
Zellen hergestellt. Ein Durchflusszytometrie basiertes Screening könnte helfen die 
produktivsten Zellen hierfür zu finden und so Medikamente effizienter herzustellen. Die 
anfängliche Entwicklung eines solchen Verfahrens wird in dieser Arbeit dargelegt. 
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Constant improvement of medical diagnostics and therapeutic treatments over the last 
decades have lead to a great increase of life expectancy in the developed world. A man 
born in Germany in the year 1960 has an average life expectancy of 67 years, whereas a 
boy born 50 years later in 2010 can now expect to live over 10 years longer to the age of 
78 (1). Although this trend is a huge success of the civilisation and a benefit for people 
who are fortunate to grow old in good health, it also has to be managed properly to keep 
the social and health care systems intact and effective. The demographical development 
imposes a series of challenges on the society as a whole but especially on organisations 
and companies that act in the environment of the health care system.  
More patients will have to be treated while fewer people will be paying contributions to 
the healthcare system. The resulting cost pressure onto the manufacturers of diagnostic 
test systems and the pharmaceutical industry is likely to increase in the future. These 
companies are forced to adapt to the changing environment and will have to innovate 
massively to keep their businesses growing and stay profitable. The innovations needed 
in this context are e.g. new products that can be produced more cost-efficiently or 
improvements of production processes that help to lower the cost of goods.  
Aptamers, a certain class of molecules, could help to meet these challenges by replacing 
more expensive substances and opening up new applications that deliver benefits for 
patients and companies in the health care market.  
In the area of diagnostic tests this could be possible by substituting antibodies in 
molecular detection assays. Flow cytometry, a widely used diagnostic method that is 
used to detect and identify different types of cells, like e.g. cancer cells, nowadays 
routinely works with antibodies. There are many references which indicate that 
aptamers are equally suited for this purpose while exhibiting longer shelf lifes at lower 
costs (2).  
In the pharmaceutical industry aptamers could be used in screening assays to find highly 
productive cells at the very start of the process development for drug manufacturing. 
Many of the newly developed drugs, especially in the area of cancer treatment are so 
called “biologics” which means that they are produced by genetically modified cells. Of 
these biologics the monoclonal antibodies (mAbs) are the most important class with 
some of them having the “blockbuster” status by reaching an annual sales of more than 
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1 billion US $. Biologics are expected to stay a huge trend for years to come and their 
efficient production is hence an important issue for keeping the drugs affordable.  
The first step in the development of the production process is the selection of a suitable 
cell clone that can be used in the final large scale cultivation process. The task is termed 
“cell line development” and involves the cultivation and screening of typically hundreds 
or even thousands of individual cell clones. An important trait of a suitable clone is its 
ability to secret the product in high amounts. A screening assay, based on cell 
immobilised aptamers that capture the secreted product and allow its quantification by 
flow cytometry is conceivable. Cells that show a good secreting performance could be 
isolated by using fluorescence activated cell sorting (FACS) and used for further 
characterisation. 
Another issue underlining the importance of cell-based drug production and its increase 
in the future is the emergence of so called “biosimilars”. Biosimilars are essentially 
generics of already approved biologics, but because of proprietary rights for the original 
cell line, biosimilar producing companies will have to select their own production cell 
lines. This fuels the need for innovative approaches to facilitate the cell line 
development. New screening assays will help to improve the efficiency of cell based 
drug production. This is crucial to ensure that new and innovative drugs will still be 
affordable for the health care system and given to patients in need.  
 
 
2 Aim and scope 
The overall goal of this thesis was the proof of principle for the application of aptamers 
in flow cytometry assays. The thesis is therefore structured in two parts that deal with 
different assay systems used to demonstrate the applications.  
One aim was to show the specific binding of aptamers to cell surface markers by flow 
cytometry and investigate potential future directions, such as the use of novel 
fluorescence labels, for this application. This study should be done with a representative 
aptamer-target system. Suitable model systems should be developed and employed to 
investigate the binding of the model aptamer and validate the system for further use. 
Later investigations should then increase in complexity until finally analysing the 
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aptamer binding to cells via flow cytometry. The same approach should then be used for 
aptamers conjugated to novel quantum dot fluorophores to assess their applicability as 
probes for flow cytometry. 
The aim of the second part of this thesis was to investigate the feasibility of an aptamer-
based screening for high secreting cells by flow cytometry. The task was to show the 
functional immobilisation of aptamers on the cell surface and the detection of bound 
target molecules. On this way, simple model systems should be studied for the 
immobilisation of aptamers and their functional evaluation by flow cytometry. Another 
aim was the development of a suitable method for the immobilisation of aptamers on 
the surface of living cells without compromising their viability. Therefore a new direct 
immobilisation approach for aptamers on the cell surface should be developed and 
compared to an already existing and rather complicated indirect approach. Finally, a 
detection method for the captured protein on the cell surface should be developed that 




3 Theoretical background 
3.1 Flow cytometry 
Flow cytometry is a bioanalytical method that measures the interaction of particles, such 
as cells, with light. Cells from a sample are suspended in a fluid stream and 
hydrodynamically focused by a second stream, called sheath fluid. By this approach the 
cells are singularized so that they pass a laser beam one after another. The method 
thereby allows collection of data on the single cell level at high throughput of up to 
thousands of cells per second. The parameters that are analysed are the light scatter 
caused by the cell and the fluorescence emitted from probes used to label the cell. The 
forward scatter correlates to the size of the cell, whereas the side scatter is a measure of 
the inner complexity and compartmentalisation of the cell. Fluorescence labelled 
reagents can be used to label intracellular structures or molecules exposed on the cell 
surface. The basic principle of a flow cytometer is shown in Figure 1. Through 
innovations in the laser, instrument and reagent technology, the amount of 
simultaniously measurable parameters has increased from 5 in the year 1995 (3) to 18 
today (4). 
 
Figure 1: Basic principle and setup of a flow cytometer. Cells are hydrodynamically focused so that they 
pass a laser one by one. The resulting scatter and fluorescence light is split into separate signals by an 
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Flow Cytometry is used for various applications in the detection and analysis of cell 
populations in clinical (6), environmental (7,8) and research applications (9). A 
widespread application is immunophenotyping, an analysis in which certain cellular 
surface molecules, known as clusters of differentiation (CD), are fluorescently stained 
with labelled antibodies to identify the cell type. The capability to rapidly analyse huge 
quantities of cells and increasing automation of the process make it a promising 
technology for the era of systems biology (10).  
Fluorescence-activated cell sorting (FACS) presents a special type of flow cytometry 
where the instruments analytical strength is combined with the capability to isolate 
certain cells from the analysed population. This is done by sorting the cells of interest 
according to their fluorescence labelling. Different technical implementations exist that 
use for example cells in liquid drops to extract them from the sample stream and collect 
them in a different tube for further cultivation or analysis (11,12). 
 
3.2 Aptamers in flow cytometry 
Aptamers are single stranded oligonucleotides that fold into distinct three-dimensional 
shapes that render them capable of binding targets with high affinity and specificity. 
Aptamers are selected against a certain target by a process called systematic evolution of 
ligands by exponential enrichment (SELEX), in which a library of ~10
15
 random 
sequences is incubated with the target and screened for binding species (13). Various 
targets have been used successfully to select aptamers, such as amino acids (14), 
proteins (15), viruses (16) and even whole cells (17). Since the discovery of aptamers 
by Ellington, Szostak, Tuerk and Gold in 1990 (18,19) the applications have spread into 
many bioanalytical areas covering capillary electrophoresis, chromatography, 
microarrays (20–22) and many more (23).  
The potential of aptamers as molecular probes for flow cytometry has been evaluated 
first in the late 1990ies with promising results (24,25). Despite the dominance of 
antibodies, that still present the standard labelling probes in flow cytometry, aptamers 
show some advantages that might attract interest for this application. Aptamers, for 
example, are accessible by chemical synthesis and can be easily modified with 
fluorophores and other functional groups. In addition they show a higher stability to 
degradation by heat or pH shifts and usually refold into their native structure after 
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thermal denaturation. These issues would alleviate handling and storage of fluorescence 
probes for customers and manufacturers. Another benefit might be their small size of 
~15 kDa which is much smaller than an antibody ~150 kDa. This might be 
advantageous for staining intracellular structures in flow cytometry assays. 
Besides the mentioned advantages another factor might favour aptamers entering the 
stage as commercially available probes: economics. The costs for oligonucleotide 
synthesis have decreased substantially over the past decade. Figure 2 shows the 
development of the costs per base of synthetic DNA for genes and short 
oligonucleotides like aptamers. It is expected that this trend proceeds or will even be 
enhanced by hundreds of siRNA projects that are currently in clinical trials, which will 
lead to expansion of the existing synthesis capacities and drive technological 
improvements in the field (26).  
 
Figure 2: Development of the costs per base of synthetic DNA oligonucleotides. Aptamers fall under the 
classification of “short oligo” shown in the graph (27).  
A comparison of assay costs between a custom synthesized RNA aptamer and the 
corresponding commercial antibody conjugate done by Zhang and his group revealed 
the small price of US$ 0.002 for the aptamer and US$ 2 for the antibody probe per 
analysis (28). This indicates that aptamers might already be cheaper today for many 
applications that use antibodies. The case why aptamers have not found a wider 
dispersion in commercial available technologies has been discussed in an interesting 
contribution by G. S. Baird (29), with the conclusion that the prevailing antibody 
technology is very well rooted and serves most needs. With regard to future 
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developments in the field of recognition molecules this will likely change. The antibody 
technology is still advancing but at a much slower pace, indicating that it might have 
reached the status of maturation shown in a typical S-curve that can be used to describe 
technology development (see Figure 3) (30). Another important aspect is that the 
original patents on the aptamer technology from the 1990s are expiring soon, granting 
freedom to operate and encouraging innovators to develop new commercial 
applications. 
 
Figure 3: The technology S-curve concept. Left: New inventions at some point enter a phase of rapid 
performance improvement that later slows down as the technology matures. Right: A hypothetical 
succession of technology S-curves that could occur in the field of recognition and targeting molecules. 
Many of the above mentioned aspects and the dynamic and diverse research 
environment in the field of aptamers support the hypothesis that aptamer technology has 
not reached this saturation yet. The future will show in which part of the “technology 
improvement” section aptamer technology is today. It is quite possible that there is still 
a huge increase of aptamer applications ahead.  
 
3.2.1 Cell-SELEX 
Cell-SELEX describes the process of generating cell specific aptamers by using whole 
cells as targets in the selection. A schematic of the approach is depicted in Figure 4. A 
pool of random oligonucleotides is incubated with live cells followed by the separation 
of bound from unbound sequences and the amplification of the bound species. The 
whole process is then repeated in successive cycles (31,32). A counterselection using 
non-target cells can be employed to eliminate sequences that bind common and 
ubiquitous structures which are cell type unspecific. At the end of the Cell SELEX 
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process the selected oligonucleotide population with the enriched aptamers is cloned 
and sequenced to identify the cell binding oligonucleotides. The enrichment of aptamers 
is typically analysed by flow cytometry. Fluorescence-labelled sequences derived from 
the selected pools are incubated with their target cells and than subjected to flow 
cytometry to measure the amount of binders. With proceeding rounds of selection the 
fluorescence signals should increase because more aptamers are enriched. Alternatively 
the enrichment of sequences can be monitored by next generation sequencing, which 
also makes the final cloning step unnecessary (33).  
The selection with whole cells is more efficient than using isolated targets because the 
molecule is present in its native environment presenting its “real” fold. If it is known 
that the target molecule requires the cell membrane or other co-receptors for proper 
folding, a Cell-SELEX is mandatory. Another option is the use of membrane fractions 
of cells, which has also been shown to yield functional aptamers (34).  
 
Figure 4: Schematic presentation of the Cell-SELEX process (2). 
 In theory, any types of cells can be distinguished by employing non target cells in a 
counterselection step. This makes the Cell-SELEX approach a promising tool for the 
development of new reagents in cancer diagnostics, therapy and research applications. 
An interesting fact is that there is no need for prior knowledge of the target molecule, as 
the aptamer evolves to the target on the cell surface during the selection process. This is 
very promising for the discovery of new biomarkers that are correlated to certain 
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diseases (35). A proof of concept has been shown for a case, where the aptamers target 
was separated and subsequently identified by mass spectrometry after a succesful Cell-
SELEX (36,37). The vast majority of the aptamer targets resulting from Cell-SELEX 
are proteins, although there are indications that it is also possible to select aptamers 
against other cell surface structures like carbohydrates and lipids (38). 
Different protocols for the implementation of the Cell-SELEX process have been 
published (39–41). A critical task is the separation of cell bound sequences from 
unbound sequences. This issue is complicated by the presence of dead cells during the 
selection. These cells are often fragmented or exhibt no intact membrane so that 
oligonucleotides can bind to intracellular or released DNA or RNA impairing the 
enrichment of aptamers (42). One option is to separate the cell-bound species by a 
simple centrifugation step that yields a pellet with the cells and the bound aptamers 
(43). Another approach is the use of fluorescence-activated cell sorting, which also 
helps to exclude dead cells with unspecifically bound sequences from the enrichment 
process (Figure 5).  
 
Figure 5: CELL-SELEX using a fluorescence-activated cell sorter (FACS) (41). 
Aptamers have been succesfully selected by the Cell-SELEX process against a variety 
of cells including eukarya (44), bacteria (45), and also virus-infected cells (46). 
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3.2.2 Current applications of aptamers in flow cytometry 
Aptamers as cost-effective labelling probes meet an increasing demand for bioanalytical 
assays. The ageing populations in western societies will lead to an even higher need for 
technologies to detect abnormal and degenerated cells. The WHO “World Cancer 
Report 2014” estimates that until 2025 the number of people diagnosed with cancer will 
rise to about 20 million, an increase of 40 % from todays figures (47). For the 
successful outcome of the treatment, early detection is a crucial factor. The 
development of cost effective sample analysis with aptamers could help to improve the 
early screening of patients worldwide. A large part of this screening could be done 
using flow cytometry assays. 
Aptamers have been applied in various applications as probes for flow cytometry, 
including cell-phenotyping, detection of cancer cell lines, virus-infected cells and 
pathogens. This topic has recently been summarized in a comprehensive review (2). 
Table 1: Applications of aptamers in flow cytometry (2): 
Application Example Reference 
Labelling of cell surface markers Labelling of CD4 positive cells Zhang et al. 2010 (28) 
Cancer cell detection Detection of small-cell lung cancer Chen et al. 2008 (56) 
Bacterial pathogen detection Detection of Staphylococcus aureus Cao et al. 2009 (65) 
Food-contamination analysis Detection of Campylobacter jejuni Dwivedi et al. 2010 (67) 
Environmental water analysis Detection of Vibrio parahaemolyticus Duan et al. 2012  (66) 
Detection of virus infected cells Vaccinia virus infected cells Tang et al. 2009 (68) 
 
Aptamers have already been selected against various cancer cell lines including 
lymphomas (44), brain (48), lung (49,50), breast (51), prostate (52) and liver (53,54).  
Especially in small-cell lung cancer (SCLC), early detection is very important, because 
the cancer cells are quickly disseminating and building metastases (55). Aptamers 
against SCLC cells have been generated using Cell-SELEX and used in various assay 
formats (56). The specificity has been enhanced by using non-small cell lung cancer 
(NSCLC) for counter selection. The selected aptamers were able to distinguish between 
the two cell types, something that is hard to achieve with common antibody assays (57). 
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Subtyping lung cancer patients with this aptamers could help to save NSCLC patients 
from disproportionately harsh treatments. Another reported case for aptamers targeting 
lung cancer cells showed the successful discrimination between lung adenocarcinoma 
cells and normal lung epithelial cells (58).  
A critical point is the adaption of the selected aptamers to analysis of real clinical 
samples derived from patients. These samples often have a complex composition and 
contain substances that can interfere with the aptamer. Shangguan et al. achieved 
promising results with aptamers evolved with cultured cancer cell lines that were also 
able to detect differences in real patient samples (53). This fuels hope that a transfer of 
aptamers developed with cell lines in the lab to routine clinical diagnostics could be 
feasible. 
Table 2: Aptamers for cancer cell detection by flow cytometry (modified from (2)): 
Aptamer Target cell 
line 







NCI-H69 small cell lung 
cancer 
unknown DNA Chen et al. 2008 
(56) 




unknown DNA Jiménez et al. 
2012 (58) 
apt1 Karpas 299 Hodgkin's 
lymphoma 
CD30 RNA Zhang et al. 2009 
(61) 
CD4 aptamer Jurkat T cell leukemia CD4 RNA Zhang et al. 2010 
(28) 
sgc3, sgd2, 
sgd3, sgc4, sgc8 
CCRF-CEM T cell leukemia unknown DNA Shangguan et al. 
2006 (44) 
A9, A10 LnCaP prostate 
adenocarcinoma 
PSMA RNA Lupold et al. 
2002 (52) 
E9P2-2 U251 brain cancer Tenascin-C RNA Hicke et al. 2001 
(48) 




HT-29 (e.g.) colorectal 
adenocarcinoma 
(e.g.) 
EpCAM DNA Song et al. 2013 
(60) 
 
Another example for an application aimed at cancer cells can be found in the work 
published by Shigdar et al. (59). They developed an RNA aptamer against the cancer 
stem cell marker EpCAM (CD326) and demonstrated that it was able to bind certain 
cancer cell lines that are known to express the stem cell marker. Other cancer cell lines 
that did not express the marker were not bound by the RNA aptamer. Another group 
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recently reported a DNA aptamer against EpCAM, which is preferred because DNA has 
a higher stability than RNA (60). Further molecules of the cluster of differentiation 
(CD) class were used as targets in the SELEX process and yielded functional aptamers 
that bound corresponding cell types, including CD30 (61) and CD4 (25). 
All of the promising results described above have to be considered critically before 
becoming over-optimistic and expecting the fast emerging application of aptamers in 
routine clinical diagnostic. The Ellington group revealed that some aptamers, which 
were reported to be specific targeting agents, showed considerable binding to a variety 
of non-target cell lines (62). 
Besides cancer cells, aptamers have been used for the detection of pathogens by flow 
cytometry. Whole bacteria cells and also viruses were employed as targets for aptamer 
selection in Cell-SELEX processes (63). This strategy provides new approaches for the 
detection of pathogen contaminated samples from environmental or food samples. 
A standard protocol for bacterial Cell-SELEX has been published with the organism 
Lactobacillus acidophilus as target (45). A modified approach using cell sorting by flow 
cytometry was recently reported by Dwivedi et al. (64) for a Cell-SELEX with the 
Salmonella serovar Typhimurium. An example with huge potential application is the 
selection of aptamers targeting the gram positive bacterium Staphylococcus aureus (65). 
Other aptamers with a potential application are described for the analysis of 
environmental samples for the presence of the pathogen Vibrio parahaemolyticus (66) 
or the analysis of food samples to detect Campylobacter jejuni (67).  
Table 3: Aptamers against pathogens for detection by flow cytometry (2): 





DNA Hamula et al. 
2008 (45) 
SA20, SA23, SA 
31, SA 34, SA43 
Staphylococcus 
aureus 







unknown DNA Hamula et al. 
2011 (63) 
ONS-23 Campylobacter jejuni unknown DNA Dwivedi et al. 
2010 (67) 
A1P, A1, A3P, A3 Vibrio 
parahaemolyticus 
unknown DNA Duan et al. 2012 
(66) 
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ST2P, ST2, ST9P, 
ST9, S8-46, S8-7 
Salmonella 
Typhimurium 
unknown DNA Duan et al. 2013 
(84); Dwivedi et 
al. 2013 (64) 
TV01, TV02, TV07, 
TV08 
Vaccinia virus unknown DNA Tang et al. 2009 
(68) 
 
Aptamers derived from Cell-SELEX have also shown to be capable of distinguishing 
between virus infected and uninfected cells. Tang et al. demonstrated this for vaccinia 
virus-infected lung cancer and Hela cells (68,46).  
Aptamer detection probes like the ones listed above could be useful for improved 
detection of various diseases caused by infectious agents which are on the rise again 
according to WHO reports (69). 
The application of aptamers for staining cell surface molecules is investigated in the 
experimental part of this thesis. 
 
3.2.3 Aptamer-quantum dot conjugates as probes for flow cytometry 
For the use of aptamers as recognition tools in flow cytometry, they have to be modified 
with fluorophores that can be excited and detected. A certain class of nanoparticles, so 
called quantum dots (QDs), have recently attracted huge interest by researchers working 
with fluorescence assays (70). QDs are inorganic semiconductors with a size between 4 
and 8 nm and show unique optical properties leading to narrow emission and broad 
absorption spectra, enhanced photostability and high quantum yield (71). Figure 6 




Figure 6: Absorption and emission spectra of CdSe quantum dots (72,73).  
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The emitted colours are depending on the size of the QDs and are red-shifted for 
increasing sizes Figure 7. Especially the possibility to excite various different QDs with 
the same excitation wavelength presents an advantage for the application in multicolour 
flow cytometry analysis using a single laser source (74,75). 
 
Figure 7: The emitted fluorescence of quantum dots is dependent on their size (76). 
 
Another interesting feature of QDs is that they can be modified with certain functional 
molecular groups and easily coupled to other molecules like antibodies or aptamers 
(77–79). Several aptamer-quantum dot conjugates have been tested for purposes like 
imaging and targeting prostate cancer cells (80,81), mouse liver cancer cells (82), 
human leukemia cells (83) and bacteria (84,85). Some of the applications used other 
bioanalytical assays than flow cytometry but in principle the detection should be 
transferable to this assay format. 
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3.3 Immobilisation of aptamers on the cell surface 
The cell surface has been recognized as a fertile ground for modifications to manipulate 
cell functions and phenotypes. Different approaches have used this strategy for basic 
research but also for development of targeting mechanisms for cell therapy applications 
(86–93). For example Dennis et al. engineered the surface of mesenchymal stem cells 
by immobilising an antibody to target the cells to activated endothelial cells (94). The 
immobilisation of molecules on the surface is not restricted to antibodies and has also 
been shown for DNA (95).  
There are two described approaches for immobilisation of molecules on the cell surface, 
that have both proved to work for aptamers as well as antibodies. Schematic drawings 
of the methods are shown in Figure 8. The first involves the chemical modification of 
amine groups exposed by molecules on the surface. The amine groups are treated with 
sulfonated biotinyl-N-hydroxy-succinimide (NHS) to couple biotin groups onto the cell. 
This step is followed by addition of the tetrameric protein streptavidin, which binds to 
the biotin and subsequently offers unoccupied binding sites. These binding sites are then 
used to attach biotinylated recognition molecules like aptamers (96). The second 
approach uses aptamers (or antibodies) that are modified with a lipid anchor (e.g. 
cholesterol or fatty acids) that is incorporated into the lipid bylayer of the cell 
membrane via hydrophobic interactions (97). 
 
  
Figure 8: Reported approaches for immobilising aptamers on the cell surface. Left: Immobilisation via a 
streptavidin/avidin bridge. Right: Immobilisation using a hydrophobic anchor. 
 
The current applications of cell-immobilized aptamers are confined to the field of cell-
surface sensors, where they are used for real time probing of cellular environments (98) 
and imaging of chemical transmitter dynamics (99). The approach used by Zhao et al. to 
detect the concentration increase of PDGF in the environment of mesenchymal stem 
cells is show in Figure 9. The cells are modified with a PDGF aptamer, that carries a 
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structural change and emits fluorescence which can be detected by fluorescence 
microscopy. The system has been used to study mesenchymal stem cells in mouse bone 
marrow. 
 
Figure 9: Basic principle of the cell-surface sensor developed by Zhao et al. (98). The sensor cells are 
modified with an aptamer and detect signalling molecules which are released by the surrounding cells. 
The detection works via a fluorophore-quencher system that emits fluorescence after binding of the 
signalling molecule. 
 
3.3.1 High-producer screening for cell line development 
Therapeutic proteins produced by cell culture processes have advanced medical 
treatments tremendously over the past two decades. The number of approved drugs of 
this class increases steadily. During the years 2006-2011 the US Food and Drug 
Administration (FDA) approved 15 novel recombinant protein therapeutics per year. 
The most successful therapeutics of this class by sales are monoclonal antibodies 
(mAbs) which account for an annual revenue of about 100 billion US$ and have been 
called “magical bullets” because of their directed and effective mechanism of action 
(100). This development, together with the advent of biosimilars and the large number 
of new biologics in the pipeline of pharmaceutical companies raises the demand for 
production cell lines with high productivity (101).  
 
Although many efforts are currently under way to increase the productivity of protein 
manufacturing by improving process technology and media composition of the cell 
culture production process (102), the key component of the biotechnological process 
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will always be the cell. Although alternatives like improved transient transfections with 
high product titers have been reported and are further explored (103), the method of 
choice for the production of antibodies will be based on stable transfected cell clones 
for a foreseeable future. The initial transfection with the product gene is usually done 
with 10
8
 cells of which ~60% get the plasmid. The resulting cell population is highly 
heterogeneous, because the product gene can be integrated at various sites of the host 
genome leading to a high variability of production characteristics (104). A huge interest 
has therefore been focused on strategies to screen cell populations and isolate individual 
clones with high productivity characteristics (105). The whole process from the initial 
transfection of the cells to the generation of stable clones for large scale pharmaceutical 
production is termed cell line development. In order to obtain correct post translational 
modifications of the therapeutic protein, mammalian cell lines are used for production 
of the majority of recombinant therapeutics (106). Chinese hamster ovary cells (CHO) 
present the most important cell line which is used in many processes because of their 
human-like glycosylation and have been engineered for improved production 
characteristics (107). Although CHO cells are used in various production processes, 
they exhibit some disadvantages compared to other production cell lines. Unlike mouse 
myeloma cells (NS0), CHO cells originate from ovary cells, which are no professional 
secretors and hence do not possess a highly evolved protein secretion machinery. 
Another disadvantage of CHO cells is their genetic instability which can result in the 
loss of production capability or product quality (108). The factors contributing to 
enhanced productivity have been investigated in various studies aimed at understanding 
the cellular physiology (109). Figure 10 shows an overview of the combination of 
attributes that are needed to yield a hyperproducer. Besides energy metabolism, redox 
balance and growth/death control, the cells capability of protein secretion is a key 
characteristic that needs to be highly developed to render it a high producer.  
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Figure 10: A high producing cell clone exhibits a combination of multiple highly developed traits that 
render it capable of synthesising and secreting large quantities of protein while still showing good growth 
characterisitics (109).  
 
The analysis of the cells secretory performance is a good starting point for evaluating 
the suitability for production processes. Different approaches for the analysis of single 
cell protein secretion have been developed to screen transfected cell populations for this 
trait (110). Many of these approaches use flow cytometry with cell sorting to identify 
and isolate single cells of interest for further characterisation. The assays that are used 
to assess the specific secretion of cells by flow cytometry use capturing of the product 
secreted by individual cells in its vicinity. Subsequently the relative product 
concentration can be determined by labelling it with antibodies and finally correlating 
its concentration with the cells secretory performance. Methods reported so far include 
gel microdrops with encapsulated cells, cold capture and affinity capture.  
The screening based on gel microdrops is based on the isolation of single cells by 
encapsulating them in a gel matrix that retains the product secreted by the cell. The gel 
used for this purpose is typically made of biotinylated agarose, which is then modified 
with streptavidin and, in a next step, with biotinylated antibodies that capture the 
product (111). An advantage of the approach is the restricted diffusion of the product, 
which is partially held back by the porous gel matrix and prevented from attaching to 
other cells, causing false positive signals. A drawback is the necessity to recover the 
cells from the gel microdroplets, mostly by enzymatic treatment (112). The screening 
has been successfully applied to select secreting hybridoma cells out of a mixed 
population with low and non secreting cells (113). 
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The cold capture screening method has been used succesfully for some hybridoma and 
CHO cell lines and showed fairly good results (114,115). The basic principle behind the 
correlation was deciphered by Pichler et al. who demonstrated that the anti-product 
antibodies precipitate with the product because of high local concentrations at the sites 
of product release from vesicles at the cell surface (116). 
Another screening approach is based on the modification of the cell surface with an 
affinity matrix that captures the secreted product and allows the detection of the 
captured proteins by labelled antibodies. The affinity matrix was originally developed to 
sort lymphocytes according to secreted cytokines but soon discovered to work as well 
for production cell lines (117,118,11). The method requires the immobilisation of anti-
product antibodies on the cell surface, which is achieved by biotinylation of the surface 
followed by incubation with streptavidin which serves as a bridge or connector to 
immobilize the biotinylated antibody (see section 3.3). A schematic of the assay 
structure is shown in Figure 11.  
 
 
Figure 11: Schematic drawing of the antibody affinity matrix. The biotinylated antibody is immobilised 
via a streptavidin/avidin (S) bridge that binds biotin (B) molecules on the modified cell surface. For 
illustrative purposes only one bound antibody is shown and sizes are disproportional. 
 
The use of avidin as a connector molecule multiplies the binding capacity because the 
tetrameric protein offers three docking sites for antibodies after immobilisation on the 
biotinylated cell surface. After modification the cells are transferred to a medium of 
high viscosity to restrict the diffusion of secreted proteins and reduce cross 
contamination of neighboring cells. The cells are then incubated to give them time to 
secret their product. After a certain time the cell-bound product is detected by a second 
labelled antibody and the cells are sorted according to their fluorescence signal. The 
highest signals should be caused by cells with a strong secretory machinery. The time 
used for incubation of the modified cells is crucial, as the binding sites on the cells are 
Cell B BS
Antibody
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limited and will get saturated with product after a certain time, eventually prohibiting a 
differentiation of high and low producers (119). 
 
Although screening of transfected cells in order to select clones suited for production of 
pharmaceutical proteins is tideous and time consuming, it is still required to establish 
economically viable processes for large scale production. The use of an antibody 
affinity matrix, which is a preferred method for screening, is hampered by several 
issues. Firstly the procedure of applying the matrix involves several steps that are 
potential stress to the cells and lowering the viability. Secondly the matrix consists of 
proteins (avidin, antibodies) from recombinant or animal sources that have to comply 
with strict regulations or are even prohibited by authorities for use in pharmaceutical 
production. A screening method based on immobilised aptamers would present an 
attractive alternative to the above described approaches and circumvent the mentioned 





4 Experimental investigations 
The aim of this work is to demonstrate the application of aptamers in flow cytometry 
assays. The experimental investigations shown below address this aim and show the use 
of aptamers in two different types of assays. The investigations are therefore divided 
into two sections. The first shows the use of aptamers for staining cell surface proteins 
and the fabrication and testing of aptamer quantum dot conjugates for this purpose. The 
second part describes the initial development of an assay for screening high secreting 
cells based on cell-immobilised aptamers and flow cytometry analysis. 
 
4.1 Aptamers as stains for cell surface proteins in flow 
cytometry  
The experimental investigations on the use of aptamers as stains for flow cytometry 
were performed with a model system consisting of the DNA aptamer TD05. The 
aptamer was selected in a Cell-SELEX process by Mallikaratchy et al. by using Ramos 
(Burkitt’s lymphoma) cells as targets (17). The group subsequently published their 
efforts to decipher the target molecule on the cell surface and suggested membrane 
bound IgM as target (137). Because of problems reported with the specificity of Cell-
SELEX derived aptamers (62), basic investigations were performed initially to verify 
the binding of TD05 to the supposed target. The experiments were done using simple 
protein microarray binding assays with IgM and other non-target proteins. Afterwards 
the binding of TD05 to Ramos cells and non-target cells was analysed by fluorescence 
microscopy before transferring the analysis to the flow cytometry format. Finally the 
aptamer was used for the fabrication of aptamer-quantum dot conjugates, which were 
then characterised and tested as labelling agents for flow cytometry. 
 
4.1.1 Basic investigations of aptamer target binding for the model system 
TD05 and IgM using microarrays 
Investigations were performed to verify the postulated target of the TD05 aptamer. 
Protein microarrays were chosen as simple test systems to check the binding of TD05 to 
isolated IgM. The assay was performed in the “reverse phase” format, in which the 
target protein is spotted onto a microarray support and then incubated with the 
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fluorescently labelled aptamer. A schematic of the assay is shown in Figure 12. Aldehyd 
functionalised glass surfaces were chosen as immobilisation substrates for the target 
protein. The aptamers were labelled with the fluorescence dye Cy3, a standard organic 
fluorophore, which is detectable with the used microarray scanner. Details concerning 
the preparation and analysis of the microarrays can be found in the appendix (6.1.1). 
 
 
Figure 12: Schematic presentation of the used “reverse phase” microarray approach to investigate aptamer 
binding to the target protein. 
 
The microarrays consisted of several blocks of spotted protein dots that comprised 
different IgM concentrations and also three negative controls. Bovine serum albumin 
(BSA), Pseudomonas fluorescence esterase I (PFEI) and fetal calf serum (FCS), a 
protein mixture, were used as negative controls. Figure 13 shows the predicted structure 
of the TD05 aptamer and a typical scan from a used microarray. The coloured dots are 
spotted target proteins that are detected by the fluorescence labelled aptamer. Target 
concentrations decrease to the right and the negative controls on the far right do not 
yield any visible signal. After aquisitation the images were analysed with the software 
GenePixPro 6.0 (Molecular Devices LLC, USA) to quantify the measured fluorescence 
intensities.  
A comprehensive analysis was set up which involved two differently labelled versions 
of the aptamer TD05, which were modified with Cy3 either at the 3’-terminus or at the 
5’-terminus. Although the predicted two dimensional structure of TD05 appears to be 
more or less symmetrically, in reality there can be influences caused by the position of 
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Figure 13: Left: Structure of the aptamer TD05 calculated using the tool Mfold (120). Right: Image of a 
microarray block with TD05 3’-Cy3 stained IgM spots. Aptamer concentration 400 nM; laser power 
100 %; gain 300. Further details can be found in section 6.1.1. 
 
In addition to the negative controls on the target site, further negative controls were 
introduced on the site of the aptamer. A defined random oligonucleotide sequence of the 
same length as TD05 was generated using the online tool “Random DNA Generator” 
provided by the Maduro lab at the University of California in Riverside. The sequence 
was also used with a Cy3 modification at the 3’-terminus. The sequences of all used 
oligonucleotides are listed in section 6.2.5. A second negative control was conceived of 
a pool of random sequences of 47 nucleotides in length. This control is termed 
“sequence pool” or “pool” in the following sections. The pool, as all other probes, were 
obtained with a Cy3 modification from a DNA synthesis company (Biospring GmbH) 
and estimated to contain 10
14 
different sequences in 60 nmol (information from the 
supplier). 
Figure 14 shows the signal intensities resulting from the microarray analysis for both 
aptamer variants and the negative controls. It can be seen that the TD05 3’-Cy3 shows 
the highest signal intensities and hence binding of the aptamer to the spotted target 
protein IgM. The signals from the protein negative controls are substantially lower. 
These negative controls were all used with the same concentration as the highest target 
protein concentration (1 mg/ml). The 5’-Cy3 labelled TD05 shows much weaker 
binding to the target protein, with signal intensities just slightly above that of the 
random or pool negative control.  
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Figure 14: Comparison of the 3’- and 5’-labelled TD05 and the random and pool negative controls. All 
aptamers and oligonucleotides were used with a concentration of 800 nM. Concentrations of protein 
negative controls BSA, FCS and PFEI were 1 mg/ml. Scanner settings: Power 100 %; gain 300. 
The data reveals a clear influence of the label position for the used aptamer TD05. The 
3’-terminus labelled variant is clearly superior with regard to target affinity. Figure 15 
shows a direct comparison and underlines this predominance. It can be concluded that 
the 5’-terminus labelled aptamer seems to be dysfunctional, which is probably caused 
by an impaired structural fold through the Cy3-fluorophore. 
 
Figure 15: Direct comparison of the signal intensities for the 3’- and 5’-labelled aptamer and the negative 
controls. The values are derived from the 1 mg/ml IgM spots incubated with 800 nM aptamer or negative 
control. Scanner settings: Power 100 %; gain 300. 
The microarray experiments confirmed the affinity and specificity of the TD05 aptamer 
for the postulated target IgM. They also revealed a probable susceptibility to misfolding 
of the aptamer depending on the labelling position.  
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4.1.2 Detection of TD05 binding to IgM beads by flow cytometry 
After confirming the binding of the aptamer model system by microarray analysis, the 
target protein IgM was immobilized on small microbeads (Dynabeads-280-tosyl) to 
transfer the analysis of TD05 binding into the flow cytometry format. The aptamers 
were now used with the fluorescence label FITC, which is an optimal fluorophore for 
the flow cytometers excitation with a blue (488 nm) laser. 
The target protein IgM and the negative control BSA were immobilised on microbeads 
and subsequently incubated with 10 µM of TD05 3’-FITC as described in 6.1.3. After 
incubation the beads were analysed by flow cytometry. 10,000 events were recorded 
and analysed for their fluorescence in the FL1 detector, which collects green light as 
emitted by FITC. Figure 16 left shows an overlay of the histograms for the BSA-
modified beads (without filling) and the IgM-modified beads (red filling). The 
fluorescence intensities of the IgM beads are higher which can be seen by the shift to 
higher FL1 values (towards right). This was also confirmed after analysis of the 






Figure 16: Left: Overlay of the histograms for the IgM beads (red filling) and the negative control BSA 
beads (no filling). Right: Fluorescence mean values obtained from the histograms. The TD05 aptamer 
shows a higher binding to the beads carrying its target protein IgM. 
It can be concluded that the binding of TD05 to its target protein can also be detected in 
a flow cytometric format, where the protein is immobilised on beads. 
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4.1.3 Microscopic investigations on TD05 binding to Ramos cells 
Before starting the analysis of aptamer labelled Ramos cells by flow cytometry, the 
cells were stained and subjected to fluorescence microscopy analysis to confirm the 
specificity and binding to Ramos cells. CHO K1 cells were used as negative control. 
Cells were cultured, prepared and incubated with 500 nM of the 3’Cy3 labelled TD05 
aptamer as described in 6.1.2 and 6.1.9. Figure 17 and Figure 18 show pictures of 
unstained and stained cells that were taken in brightfield mode and with the 
microscopes filter suitable for Cy3 detection. None of the cells show any 
autofluorescence that would result in false positive signals after the staining process.  
 










Figure 17: Microscopic analysis of unlabelled Ramos and CHO cells in brightfield mode (top) and with 
the NG filter (Exc. 530-550; Em. BA 590) which is later used for Cy3 detection (bottom). Both cell lines 
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Figure 18: Microscopic analysis of TDO5-Cy3 labelled Ramos and CHO cells. Pictures were taken in 
brightfield mode (top) and with the NG filter (Exc. 530-550; Em. BA 590) to detect the Cy3 label. There 
is no observable binding to the negative control cells (CHO) whereas Ramos cells are stained by the 
aptamer. 
Pictures of the aptamer stained cells are shown in the lower section Figure 17. The 
results confirm the binding of the TD05 aptamer to the Ramos cells, which are clearly 
stained. Only one or two faint signals are found on the picture showing the negative 
control cells resulting from unspecific binding. 
 
4.1.4 Detection of TD05 binding to IgM on Ramos cells by flow cytometry 
After demonstrating the ability to detect the binding of the aptamer to cells via 
fluorescence microscopy, it was finally tested with living cells in a flow cytometer. The 
original target cells which were used in the cell SELEX procedure were cultured and 
taken for the analysis.  
The cells were prepared and incubated with 1 µM of FITC-labelled aptamers as 
described in 6.1.4. After incubation the cells were analysed by flow cytometry. The 
histograms resulting from the FL1 detector (FITC fluorescence) were subjected to a 
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marker analysis. The marker was set so that less than 1 % of the unlabelled cells were 
found in the marker region. The other samples were analysed and the percentage of cells 
falling into the set marker region served as an indication how many aptamers bound to 
the cell. Figure 19 shows the principle of the marker analysis. 
  
Figure 19: Principle of the marker analysis used to detect aptamer stained cells. Left: Unstained Ramos 
cells. Right: Ramos cells stained with the FITC labelled aptamer. The percentage of cells found in the 
marker region (M1) are denominated as positive.  
The results are depicted in Figure 20 were the percentage of cells stained with the 
aptamer can be seen. Again several negative controls were included in the experiment to 
assure the results. The random oligonucleotide and the sequence pool were incubated 
with the Ramos cells to test if the binding to the cell surface is unspecific and sequence 
independent. CHO K1 cells served as simple negative controls on the cell site to test the 
specificity and eliminate the possibility that the aptamer recognizes common structures 
generally found on the cell surface. 
The data presents a clear specificity of the TD05 aptamer to the Ramos cells. The 
aptamer neither binds the non-target CHO cells nor does a comparison with the random 
and pool sequences reveal a general affinity of oligonucleotides to Ramos cells. In 
contrast to the microarray experiments there is no difference between the two 
differently labelled variants. 
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Figure 20: Comparison of Ramos and CHO cells labelled with the two aptamer variants TD05 5’-FITC 
and TD05 3’-FITC and the negative controls random and pool. The marker analysis shows that over 90 % 
of the Ramos cells are stained by the aptamers, whereas the unspecific binding to CHO cells stains less 
than 10 % of the cells. The percentage of Ramos cells stained by unspecific binding from random and 
pool are also below 10 %. 
The reason for this is not obvious but it can be speculated that it is caused by the 
orientation and accessibility of the target protein for the 5’-labelled aptamer. For the 
microarray analysis the protein is spotted onto the microarray surface, resulting in a 
random orientation of the target molecule. On the cell surface, the IgM will have a more 
defined orientation that can be bound by the 5’-labelled aptamer. In the microarray 
assay this aptamer probably fails to bind most of the deposited IgM on the surface. 
After confirming the specificity of the aptamer TD05 to Ramos cells, a concentration 
series of the two differently labelled aptamers was incubated with the target cells to 
estimate a binding constant for the interaction with the cell bound IgM (17). 
The samples were prepared and incubated as described (6.1.1) and afterwards analysed 
by flow cytometry to measure the fluorescence of the cell bound aptamers. Figure 21 
shows the resulting fluorescence intensities for the different aptamer concentrations. 
The fluorescence reaches a saturation for concentrations over 100-200 nM. The 
comparison to the negative control consisting of the pool of labelled sequences confirms 
again the specificity of the binding.  
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Figure 21: Analysis of Ramos cells incubated with concentration series of the two differently labelled 
TD05 variants and the negative control pool. The fluorescence reaches saturation for concentrations 
above 100-200 nM. 
The data was used to fit a logistic function to the fluorescence values with the software 
QtiPlot (Figure 22). The estimated binding constant (KD) can afterwards be extracted as 
the value of the inflection point (x0) of the fitted curve. The analysis yields an estimated 
KD of 82.89 nM for TD05 3’-FITC and an estimated KD of 115.5 nM for TD05 5’-
FITC. The obtained results are similar to the publicated values of ~75 nM for the 
aptamer TD05 (17). 
 
  
Figure 22: Plots show the curve fitting used to estimate the aptamers binding constants for the aptamer 
cell interaction. Left: TD05 3’-FITC with a KD of 82.89 nM. Right: TD05 5’-FITC with a KD of 115.5 
nM.  
Further experiments focused on the validation of the postulated target IgM, which is 
expected to be the cell bound target of the aptamer. Although the microarray analysis 
and cell binding studies support this assumption, an additional test was carried out to 
assure that the aptamers target is indeed a protein. This was done by incubating the 
Ramos cells with a solution containing proteinase K and comparing it to untreated cells 
in an aptamer binding assay. The proteinase K treatment should lead to a digest of 
protein structures on the cell surface, thereby destroying the target of the aptamer. The 
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sample preparation was done as described (6.1.5) and the cells finally subjected to the 
standard flow cytometry measurement.  
 
 
Figure 23: Comparison of aptamer binding to proteinase K treated cells and untreated cells. The treated 
cells exhibit less target molecules and show lower aptamer binding. 
The results are illustrated in Figure 23 and show considerably lower amounts of cell 
bound aptamers on the proteinase K-treated cells compared to the untreated cells. This 
data further supports the identity of IgM as the target molecule on the surface of Ramos 
cells. 
Another negative control was tested to ascertain the specificity of the aptamers cell 
targeting. The cell line CCRF-CEM was chosen as it is closely related to the Ramos cell 
line because both originate from human lymphocytes. The cells should hence have a 
higher similarity of the cell surface structure than the previously used CHO cells and 
present a higher challenge to the aptamers specificity.  
The CCRF-CEM cells were cultured as described (6.1.9) and then incubated with 
aptamers by the same procedure used for Ramos cells (6.1.4). Figure 24 presents the 
results of flow cytometry analysis with concentration series of the TD05 aptamer and 
the sequence pool. There is no detectable binding of any of the used probes to the 
CCRF-CEM cells. The aptamer is hence also able to differentiate between closely 
related cell lines. 
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Figure 24: Analysis of the non-target cell line CCRF-CEM with the two differently labelled aptamer 
variants and the negative control sequence pool. The aptamer TD05 shows no affinity to the CCRF-CEM 
cells. 
 
4.1.5 Aptamer-quantum dot conjugates targeting Ramos cells 
After confirming the affinity and specificity of the DNA aptamer TD05 to Ramos cells 
in the previous experiments, it was now used for fabrication of aptamer-quantum dot 
(QD) conjugates. Quantum dots are semiconductor nanoparticles that posses unique 
optical properties that make them interesting labels for bioanalytical applications like 
flow cytometry (3.2.3). For the use in cell-specific staining they have to be coupled to a 
recognition molecule like an antibody or an aptamer. Due to the great potential of cell 
SELEX derived aptamers, the conjugation of aptamers to QDs is particularly promising. 
The aptamer TD05 was chosen to construct such conjugates and characterize their 
binding properties. 
The conjugation procedure used for fabrication of the TD05-QD655 conjugates is 
described in detail in section (6.1.6). In a nutshell, amino-modified aptamers were 
activated with EDC and coupled to carboxyl-modified quantum dots, resulting in a 
covalent binding of the aptamers to the QDs surface. After conjugation, the constructs 
were characterized by microarray binding studies. It was tested if the aptamer was still 
able to bind the target molecule IgM after conjugation to QDs. The same experimental 
layout as in section 4.1.1 was used to study the interaction. 
Different IgM concentrations and protein negative controls were spotted onto a 
microarray support and subsequently incubated with the aptamer-QD conjugates. 
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Figure 25: Schematic presentation of the used “reverse phase” microarray approach to investigate 
aptamer-QD conjugate binding to the target protein. 
The experimental procedure for the microarray preparation and analysis is described in 
(6.1.1). The microarrays were scanned with the laser setup suitable for the detection of 
QD655, which present red QDs with 655 nm emission wavelength. Figure 26 shows an 
image of a typical microarray block on the left. The red stained dots are immobilised 
IgM, the negative controls are further on the right and give weak or no signals. The 
right part of the figure presents the data obtained from the image analysis by using the 
software GenPixPro 6.0.  
  
Figure 26: Characterisation of aptamer-QD conjugates by microarray binding studies. Left: Typical image 
of a scanned protein microarray block incubated with the conjugates. The block consists of four columns 
of the target molecule IgM (1, 0.5, 0.1, 0.01 mg/ml, from left) and two negative controls further right 
(BSA and FCS with 1 mg/ml). Each column consists of 9 replicates. Right: Results of the image analysis 
for the shown block. The conjugate concentration was 40 nM.  
The data shows that the TD05-QD655 conjugates are able to specifically bind the target 
molecule IgM on microarrays. Very weak signals are obtained for the two negative 
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Afterwards a concentration series of the conjugates was used to incubate microarrays 
with deposited IgM. Figure 27 shows the signal intensities for conjugate concentrations 
from 10 nM to 60 nM. As expected there is a signal increase with higher concentrations. 
 
Figure 27: Concentration series of the aptamer-QD conjugates incubated with the target protein IgM 
(0.5 mg/ml) on microarrays. Increasing concentrations yield higher fluorescence signal caused by binding 
of more conjugates to the protein spots.  
The conjugates were subsequently used for cell staining experiments. Ramos and CHO 
cells were incubated with the conjugates at concentrations of 3 nM and 30 nM. The 
detailed sample preparation procedure can be found in section (6.1.7). The cells were 
finally analysed by flow cytometry to measure the fluorescence of the cell bound TD05-
QD655 conjugates in the FL3 (red) detector of the cytometer.  
  
Figure 28: Analysis of Ramos and CHO cells stained with the aptamer-QD conjugates. Left: Cells 
incubated with 3 nM of the TD05-QD655 conjugate. Right: Cells incubated with 30 nM of the TD05-
QD655 conjugate.  
It can be seen that the Ramos cells incubated with the conjugates show a higher 
fluorescence mean value than the non-target CHO cells. But the difference is not 
significant because the binding of the aptamer-QD conjugates to CHO cells exhibits 
large error bars. A reason for the unspecific binding could be the non-specific cellular 
uptake of the conjugates which has been reported to occur frequently for coated 
nanoparticles (121).  
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The fabrication of functional aptamer-QDs with specificity to the target protein could be 
shown in microarray binding experiments. However, the conjugates failed to exhibit this 
specificity when analysed with the target Ramos cells. Unspecific binding to non-target 
cells presents a challenge for the routine application of these stains for flow cytometry. 
By further improving the labelling procedures and washing steps it could be possible to 




4.2 Immobilisation of aptamers on the cell surface and their 
characterisation by flow cytometry 
While many examples of applying aptamers in cell staining for flow cytometry exist, 
the literature on cell-immobilised aptamers is relatively scarce. The applications of cell-
immobilised aptamers until now are found in the field of biosensors as described by 
Zhao et al. (98). The goal of this work is to demonstrate the use of a cell-immobilised 
aptamer affinity matrix for screening protein producing cells in order to identify the 
cells that secret the most product. These cells are assumed to be the best producers and 
it would be beneficial to select them early in cell line development to speed up further 
process development and identification of cell lines for efficient production. 
Aptamers are chemically synthesized molecules that can be easily produced under GMP 
regulations that apply for pharmaceutical production. Furthermore they can be 
specifically functionalised which should allow a directed immobilisation on cells. 
Ideally an aptamer based molecular beacon (consisting of a fluorophore-quencher 
system) is conceivable that would allow the detection of secreted molecules without the 
use of a second detector molecule. Figure 29 shows schematic drawings of potential 
high producer assays based on immobilised aptamers. 
 
  
Figure 29: Principle of high producer assays based on immobilised aptamers. Top: Capturing of secreted 
proteins by cell surface-immobilised aptamers followed by detection of bound protein by a second 
fluorescently labelled aptamer. Bottom: Principle of a high producer assay based on an immobilised 
aptamer beacon. Bottom 1: If the aptamer is not interacting with the target protein, a quencher (Q) 
silences the attached fluorophor (F). Bottom 2: During binding of the target protein the aptamer 
Cell
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undergoes a structural change to fit to the target, thereby separating fluorophor and quencher which leads 
to an increase of the fluorescence signal. 
 
An antibody based affinity matrix has been evaluated for screening in the cell line 
development process but has, however, failed to establish itself as a common standard 
(11). This might be because of the complicated modification of the cells that is needed 
to build up the antibody affinity matrix, which might not justify the procedure when 
reasonable results can be achieved by using easier methods for identifying high 
producers (115). Using aptamers as recognition tools prevents the problems associated 
with introducing additional proteins like antibodies into the cell line development 
process, which is subject to strict regulations under GMP. The ability to specifically 
modify aptamers within their sequence also opens up the possibility to immobilise 
aptamers in a directed and uncomplicated way on the cell surface. These features, paired 
with the option of selecting aptamers against virtually all kinds of molecules which are 
currently produced in cell based biotechnological processes, make it worth to explore 
the potential and feasibility of immobilising intact aptamers on living cells. Initial 
experiments were carried out with beads, which served as simple cell models to test the 
immobilisation and the possibility to detect the aptamer target interaction in a flow 
cytometer. Figure 30 shows a schematic of the general experimental approach. 
 
 
Figure 30: Schematic of the experimental investigations. Aptamers were immobilised on beads or cells 
using different immobilisation strategies and afterwards incubated with fluorescently labelled target 
protein. The amount of bound target was then analysed by flow cytometry. 
 
 
4.2.1 Indirect immobilisation of aptamers using a biotin streptavidin bridge 
As a first approach to immobilise aptamers on cells the modification of the cell surface 
with biotin and streptavidin followed by immobilisation of biotinylated aptamers is 
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investigated. The streptavidin molecule thereby serves as a bridge between the 
biotinylated cell surface and the biotin modified aptamer. The immobilisation concept is 
shown in Figure 31. The approach seems complicated but has successfully been used to 
immobilise antibodies on the cell surface, indicating that this might work with aptamers, 
too. The immobilisation was first done on streptavidin coated beads which served as 
simple model system to test the approach. 
 
Figure 31: Scheme of the aptamer immobilisation approach using a biotin-streptavidin “bridge”. 
Biotinylated cells are incubated with streptavidin and afterwards with biotin modified aptamers. 
 
4.2.1.1 Indirect immobilisation – proof of principle using streptavidin modified 
beads 
Streptavidin coated beads with a diameter of 2.8 µm were incubated with a lysozyme 
aptamer that was biotin-modified at the 5’-terminus and fluorescently labelled at the 3’-
terminus (122). The incubation was done according to the suppliers protocol (6.1.13). 
After incubation and washing, the beads were analysed by flow cytometry to measure 
the fluorescence of the labelled aptamer. Figure 32 shows that the binding of the 
biotinylated aptamers to the streptavidin coated beads is successful and that a saturation 
of the beads with aptamers can be observed for aptamer concentrations above 50 nM. 
 
Figure 32: Proof of immobilisation of biotin and FITC-modified aptamers on streptavidin beads. 
Cell B BS
Aptamer
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After showing the successful immobilisation of biotin-modified aptamers on the 
streptavidin-coated beads, aptamer-modified beads were incubated with the 
fluorescently labelled target protein. A lysozyme binding aptamer was chosen as a test 
system for this study (122). Aptamer beads were freshly prepared according to the 
manufacturers protocol (6.1.13). 2 µl of the resulting bead solution were incubated with 
500 µl lysozyme-FITC for 30 min in the dark at room temperature in a rotator. 
Afterwards the beads were washed with 300 µl aptamer binding buffer with additional 
50 mM NaCl for further 30 min. Finally the samples were analysed by flow cytometry 
to measure the fluorescence of the bead bound target. The negative control consisted of 
beads modified with the aptamer 264 which is not supposed to bind lysozyme. The 
results in Figure 33 show stronger binding of the lysozyme to the negative control beads. 
This might be a result of high unspecific binding of lysozyme to the streptavidin beads 
or due to problems with the aptamers fold which might be impaired after the 





Figure 33: Left: Incubation of lysozyme aptamer-modified streptavidin beads with the target protein. The 
results show a higher binding of the target to the negative control which was modified with an aptamer 
that was not selected against lysozyme. Right: Structure of the lysozyme aptamer calculated with Mfold 
(120). 
To investigate if the incapability of the aptamer beads to specifically bind their target is 
generic or only a result of the chosen lysozyme aptamer, another aptamer-target system 
was chosen. The aptamers Del5-1 and V7t1 which target the vascular endothelial 
growth factor (VEGF) were chosen for this purpose (123,124). The predicted aptamer 
structures can be seen in Figure 34.  
The target protein VEGF was produced using a recombinant E.coli strain and purified 
as described in (6.1.10). After purification the protein was labelled with the 
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fluorescence dye FITC by standard procedures (6.1.11) and its concentration 
determined using a micro-BCA assay.  
 
  
Figure 34: Calculated structures for the two VEGF binding aptamers V7t1 (left) and Del5-1 (right) using 
the tool Mfold (120). 
 
After immobilisation of the two biotin modified aptamers on the streptavidin beads, the 
modified beads were incubated with fluorescently labelled VEGF for 30 min in the dark 
at RT in a rotator. Afterwards the samples were analysed by flow cytometry. The 
negative control was the same as used above for the lysozyme aptamer. Figure 35 shows 
that one of the aptamers (V7t1) binds the target while the second (Del5-1) only yields 
fluorescence signals on the same level as the negative control. It can be concluded that 
the binding of targets by aptamers immobilised on streptavidin coated beads is possible 
but depends on the used aptamer. 
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Figure 35: Incubation of VEGF aptamer-modified streptavidin beads with VEGF-FITC. The aptamer 
V7t1 shows higher signal intensities than the aptamer Del5-1 which exhibits the same binding as the 
negative control. 
 
4.2.1.2 Immobilisation of aptamers against IgG on the cell surface 
As a model system for investigating whether aptamers stay functional after 
immobilisation on the cell surface the aptamer 264 and its target the Fc-fragment of 
human IgG antibodies were chosen. CHO K1 cells were used as immobilisation 
substrates because of their widespread application in biotechnological production (102). 
Figure 36 is an illustration of the predicted structure for the aptamer, consisting of a 
stem-loop motif. 
 
Figure 36: Structure of the aptamer 264 calculated using the tool Mfold (120). 
The model system also presents a starting point for a potential application of an aptamer 
based affinity matrix on cells. A similar approach, based on immobilized antibodies, has 
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been used in cell line development for screening and sorting monoclonal antibody 
(mAb) secreting cells by FACS (117). An aptamer-based version of this assay could 
help to improve efficiency of cell line development by screening for high producers 
early in the process. 
To demonstrate the immobilisation approach step by step, all modifications involved in 
building up the aptamer affinity matrix were investigated. A schematic of the 
immobilisation is shown in Figure 31. Each step was performed with a fluorescence 
label at the respective component (cell-surface biotinylation agent, streptavidin and 
biotinylated aptamer) to prove that the modification of the cells works as intended. 
Firstly the reactive N-Hydroxysuccinimide (NHS) ester which is used to biotinylate the 
cell surface was used as a NHS-FITC derivative. Cells were incubated for different 
times with increasing concentrations of the component and analysed via flow 
cytometry. The NHS binds to primary amino groups that should be present on the cell 





Figure 37: Binding of different NHS-FITC concentrations to the cell surface. The highest concentration 
(1000 µM) yields the highest signal. 
The data in Figure 37 proves that the NHS-ester is capable of binding to amino groups 
of structures on the cell surface. It further shows that the amount of bound NHS-FITC 
depends on the concentration used to incubate the cells. The highest concentration 
yields the strongest fluorescence signal. The reaction appears to be very fast as only 
slight increases in fluorescence can be seen when comparing the samples analysed after 
one and five minutes. For all further experiments a concentration of 1000 µM NHS-
biotin and an incubation time of five minutes were used. 
Cell
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As a next step the binding of streptavidin to the biotinylated cell surface was 
investigated by incubating biotin modified cells with FITC labelled streptavidin. The 
cells were subsequently analysed by flow cytometry and showed increasing 
fluorescence at higher concentrations (Figure 38). For concentrations higher than 
25 µg/ml the fluorescence reaches saturation. To assure that this saturation is reached 





Figure 38: Binding of streptavidin-FITC to biotinylated cells.  
To show that the last step, the immobilisation of biotinylated aptamers takes place, 264 
aptamers with biotin at the 5’-terminus and FITC at the 3’-terminus were incubated with 
the prepared cells (Figure 39). Figure 40 illustrates that increasing concentrations of the 
aptamer used for immobilisation yield higher fluorescence signals. For the later 
experiments with the complete assay, 6 µM biotinylated aptamer were used. Negative 
controls were analysed to demonstrate that the immobilisation of the aptamer is specific 
for the biotin-streptavidin treated cells and does not result from unspecific binding of 
the aptamer to the cells. The data proves that the immobilisation approach works and 
that it requires the complete prior modification protocol with biotin and streptavidin. 
Figure 40 also shows that no aptamer can be immobilised if one of the components 
(biotin/streptavidin) is left out.  
 
Figure 39: Proof of aptamer immobilisation via biotin-streptavidin: A fluorescence labelled aptamer is 
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Figure 40: Immobilisation of biotin-modified and fluorescently labelled aptamers in the last step of the 
matrix build up. Left: Fluorescence intensities for increasing concentrations used for incubation of the 
cells. Right: The immobilisation only takes place on cells modified with biotin and streptavidin. 
After proving that the intended immobilisation procedure can succesfully be applied, it 
was investigated whether the aptamer stays functional. Aptamer modified cells were 
incubated with fluorescently labelled target (Fc-fragment-FITC). Although the affinity 
of the aptamer had not been determined an estimation based on microarray experiments 
expected it to be in the nanomolar range (125). Therefore target concentrations for 
initial experiments were set to 2-6000 nM. As negative controls and to investigate 
unspecific binding by the Fc-fragment, samples lacking NHS-biotin, streptavidin and 
the aptamer were incorporated in the analysis. The results show that although the 
binding to the cells increases with higher target concentrations, the interaction is 
unspecific and binding is also found for all negative controls (Figure 41). It can be 
concluded that there is unspecific binding of the Fc-fragment to the cell surface. In 
addition the actual specific binding of the target by the aptamer could be impaired by 
steric effects. 
  
Figure 41: Fluorescence of the aptamer modified cells after incubation with the target molecule Fc-FITC. 
Left: Concentration series of the target and resulting fluorescence intensities. Right: Comparison of 
fluorescence intensities for the modified cells and negative controls for 2000 nM target.  
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To exclude possible interference of the aptamers which could occur by too dense 
immobilisation, samples with different concentrations of immobilised aptamers were 
analysed. The modified cells were all incubated with 10 µM of the fluorescently 
labelled Fc-fragment. Figure 42 shows that the concentration of aptamer which is used 
to incubate the cells during immobilisation has no effect on the binding of the Fc-
fragment. The fluorescence of modified and unmodified cells does not differ when 
measured directly after incubation or after centrifugation and resuspension of the cells 
in binding buffer. After resuspension of the cells the fluorescence descreases strongly 
which indicates a weak binding of the target to the modified cells. 
 
Figure 42: Binding of the target to cells modified with different aptamer concentrations. Directly after 
incubation (left bars, light grey) and after centrifugation and resuspension of cells in binding buffer (right 
bars, dark grey). 
To investigate if the aptamer is not functional because of steric hindrance from the 
relatively large streptavidin molecule, a spacer system was used to increase the distance 
between the aptamer and the streptavidin bridge. The spacer consists of a double 
stranded DNA section which is formed between a biotin modified oligo and its 
complementary sequence which is used as direct elongation of the aptamer sequence 
(98). The oligonucleotide sequences are listed in appendix 6.2.5. An illustration of the 
approach can be seen in Figure 43. 
The structure of the aptamer with the elongated sequence was again used to calculate its 
predicted structure. The structures with spacer and without are shown in Figure 44. The 
predicted structures do not differ significantly and show no indication that the spacer 
might interfere with the aptamers fold. 
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Figure 43: Proof of aptamer immobilisation using a DNA helix spacer. After hybridisation and 




Figure 44: Comparison of the aptamer fold for 264 without (left) and with the described spacer elongation 
(right). The stem-loop structure of the aptamer is not effected. Structures were calculated using Mfold 
(120). 
Cells were modified with biotin (1 mM NHS-biotin) and streptavidin (50 µg/ml) as 
described in section 6.1.17 and subsequently incubated with different concentrations of 
the 264 aptamer containing the DNA helix spacer. The aptamer also contained a FITC 
label at the 3’-terminus of its sequence. The fluorescence values of the modified cells 
increase with higher concentrations of the aptamer, indicating a successful 
immobilisation of the aptamer with the spacer. A saturation of the streptavidin on the 
cell surface can be observed for concentration of 5 µM aptamer or higher. However, 
also with consideration of the different labelling ratios of the aptamers, the fluorescence 
values are slightly lower than for the aptamer without spacer (Figure 45). The 
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Figure 45: Left: Immobilisation of increasing concentrations of aptamer. Right: Comparsion of resulting 
fluorescence intensities for cells modified with fluorescently labelled aptamers with the above described 
spacer and without (different labelling ratios of the oligos were taken into account).  
The effect of the spacer on target binding was investigated by comparing it to 
unmodified cells and the aptamer without spacer. The aptamers were immobilised as 
described above and incubated with high concentrations of the Fc-fragment (20 µM and 
40 µM). The cells were subsequently analysed by flow cytometry. The results in Figure 
46 show no difference between the aptamer with spacer and without. The spacer could 
not help to achieve a succesfull binding of the immobilised aptamer to the Fc-fragment. 
  
Figure 46: Binding of fluorescence labelled Fc-fragment to aptamer modified cells using aptamers with a 
DNA double helix spacer compared to unmodified cells and an aptamer without spacer. Left: 20 µM 
target concentration. Right: 40 µM target concentration.  
 
Determination of aptamer-affinity against IgG by MST 
After several failed attempts to detect binding of the cell-immobilised aptamer 264 with 
the Fc-fragment, the affinity of the aptamer was determined by microscale 
thermophoresis. Microscale thermophoresis (MST) is a method to measure binding 
constants of two partners. It presents an alternative to methods such as isothermal 
titration calorimetry (ITC) or surface plasmon resonance (SPR). The MST principle is 
described in section 6.1.20. 
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The aptamer 264 was analysed with the Fc-fragment and also with an intact polyclonal 
human IgG antibody. The experiments reveal very low affinities for both interactions. 
The analysis of the aptamer binding to the Fc-fragment yields a dissociation constant 
(KD) of 28 µM or higher. But according to the data, the affinity is probably lower 
because there is no data point supporting the saturation of the binding curve in figure 
Figure 47. For the analysis of the aptamer 264 binding to the IgG antibody there is no 
detectable binding at all, which might be due to problems with the buffer conditions that 
cause considerable noise in the data (Figure 47). A reason for this could be the 
agglomeration of IgG or the adherence to capillary walls in the MST device which 
could prohibit the correct measurement of the aptamer-target interaction. 
 
 
Figure 47: Determination of binding constants by microscale thermophoresis. Left: Binding of the 
aptamer 264 to the Fc-fragment. The binding constant is at least 28 µM. Right: Binding of the aptamer 
264 to a human IgG antibody. For this experiment no binding is detectable at all. 
It must be concluded that the aptamer target system consisting of the aptamer 264 and 
the Fc-fragment of human IgG antibodies reveals to be unsuitable for demonstrating a 
proof of principle for the intended assay. To show that the problems are mainly caused 
by the aptamer itself and its poor affinity another aptamer target pair was chosen for 
further experiments.  
 
4.2.1.3 Indirect immobilisation of VEGF aptamers on the cell surface 
The aptamers V7t1 and Del5-1 against the human vascular endothelial growth factor 
(VEGF) show high specificity and affinities in the nanomolar range according to 
literature (124,123). The sequences of both aptamers can be found in the appendix 
6.2.5. The binding constants were determined through MST measurements by Maren 
Lönne in an ongoing dissertation and yielded KD values of 75 nM for Del5-1 and 23.2 
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nM for V7t1. For immobilisation via biotin and streptavidin the aptamers were used 
with biotinylation at their 3´-end.  
The two aptamers were immobilised by the same procedure used above for the aptamer 
264 without DNA helix spacer. The modified cells were subsequently incubated with 
FITC labelled VEGF in a concentration range from 100-1200 nM. The aptamer 264 was 
used as a negative control because it should not show any affinity to VEGF. The cells 
were analysed by flow cytometry after incubation. The experimental data in Figure 48 
show that aptamer Del5-1 stays functional after immobilisation and is able to bind 
fluorescently labelled VEGF. The fluorescence signals of the aptamer V7t1 are lower 
but still above the negative controls.  
 
Figure 48: VEGF binding to aptamers immobilised via biotin-streptavidin on cells. Both investigated 
aptamers show binding of the fluorescence labelled VEGF after immobilisation via biotin-streptavidin on 
the cell surface. 
Although the immobilisation of functional aptamer using a biotin-streptavidin bridge 
could be shown successfully for the VEGF aptamer Del5-1, problems with the other 
aptamers might result from the immobilisation approach. The modification of the cells 
using biotin and streptavidin is also very complicated, tedious and time consuming. The 
reasonable conclusion of this is the evaluation of other immobilisation approaches. 
Later sections therefore investigate the potential of immobilising aptamers directly on 
the cell surface (4.2.2). 
 
4.2.1.4 Indirect immobilisation of aptamers on the yeast Pichia pastoris 
After showing the immobilisation of aptamers on the surface of CHO cells it was tried 
to show that the modification with biotin, streptavidin and an aptamer can also be 
applied to other cell types and organisms. For this purpose another biotechnological 
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important organism, the yeast Pichia pastoris, was chosen as subject. Pichia pastoris is 
used in various processes for the production of recombinant proteins or vaccination 
compounds like virus like particles (126). Because these processes would also benefit 
from a high secretor screening, Pichia pastoris is an interesting model for this study.  
The Pichia pastoris host strain GS115 was obtained as kryo culture from Maria Zahid 
(co-worker, Institut für Technische Chemie) and cultivated as described in the appendix 
6.1.9. To test if the immobilisation via biotin-streptavidin is possible on the surface of 
P. pastoris, the cells were incubated with NHS-FITC of increasing concentrations and 
analysed by flow cytometry. NHS is the active chemical that is used in combination 
with biotin for the biotinylation of the cell surface in the first step of the immobilisation 
assay. It binds to available amino groups that should also be found on P. pastoris cells. 
After binding, the immobilised FITC should than be detectable by flow cytometry. As 
Figure 49 shows NHS-FITC is able to bind to the cell surface. Increasing concentrations 
lead to higher fluorescence values. For all further experiments the highest concentration 
of 1000 µM was chosen. A microscopic image in Figure 49 also shows the successful 
labelling of the cells. 
  
Figure 49: Labelling the yeast P. pastoris with NHS-FITC. The cell surface of the cells is also accessible 
for the reactive compound. 
As a next step the cells were modified with NHS-biotin and incubated with streptavidin-
FITC to test if streptavidin can be bound by the biotinylated cell surface on P. pastoris 
cells. Figure 50 shows the flow cytometry analysis of the modified cells. It proves that 
streptavidin is bound and yields increasing fluorescence intensities with higher 
concentrations.  
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Figure 50: Analysis of P. pastoris after biotinylation and incubation with streptavidin-FITC. The protein 
binds to the biotinylated cell surface. 
The results indicate that P. pastoris also fulfills the requirements for immobilising 
aptamers by the biotin-streptavidin approach. To investigate if the modifications with 
biotin, streptavidin and the aptamer have any influence on the cultivation of the yeast, a 
comparative cultivation was performed with an aptamer modified and an unmodified P. 
pastoris culture. The biotinylated aptamer 264 was used as a model for this study and 
immobilised as described in the appendix 6.1.17. The cultivation was done in BMGY 
media (buffered glycerol-complex medium), which consists of 1 % (w/v) yeast extract, 
2 % (w/v) peptone, 100 mM potassium phosphate, 1.34 % (w/v) YNB (yeast nitrogen 
base), 4 x 10
-5
 % (w/v) biotin, 0.004 % histidine (w/v) and 1 % glycerol with a pH of 
6.0. The cultures were inoculated by adding 3 ml of modified P. pastoris with an OD600 
of 1 to 27 ml of medium in 250 ml shake flasks. The temperature and agitation were 
kept constant at 30°C and 250 rpm. 
 
 
Figure 51: Comparative cultivation of modified and unmodified P. pastoris cells.  
Figure 51 depicts the cell density monitored by measuring the OD600. The two cultures 
show no difference in their growth behavior. The modification and development of an 
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assay based on immobilized aptamers should therefore also be applicable for P. pastoris 
intended for further cultivation.  
 
 
4.2.2 Direct immobilisation of aptamers  
Direct immobilisation of aptamers on the cell surface would be beneficial because of 
time and cost savings. In addition the process would work without introducing 
proteinogenic substances like streptavidin, which can be complicated in GMP regulated 
processes like cell line development. Furthermore the procedure would be 
straightforward compared to the multiple steps needed for the modification with biotin 
and streptavidin as described in 4.2.1. Due to the ease of modifying aptamers, they can 
be used with an activatable group at one of their ends, which can then be used for 
coupling to other functional groups. 
 
4.2.2.1 Direct immobilisation – proof of principle using beads as immobilisation 
substrates 
Prior to investigating the direct immobilisation of aptamers on the cell surface, 
experiments with aptamers directly bound on beads were carried out. Aptamer modified 
beads have recently been shown to work as protein detection platforms in flow 
cytometry (127). Here the experiments were thought as initial step to study the aptamer 
target binding for later cell based studies. 
Beads with immobilised lysozyme aptamer 
The DNA aptamer targeting lysozyme was chosen as model system because of the good 
and cheap availability of its target. The aptamer originates from an affinity capillary 
electrophoresis-based SELEX and has been used in a chromatographic application 
(128). The binding constant was described to be in the nanomolar range by different 
techniques (122). The aptamer sequence (Lys-Apt) can be found in appendix 6.2.5. 
The immobilisation on beads was performed according to the standard protocol 
presented in appendix 6.1.14. Shortly, amino modified aptamers were incubated with 
EDC-activated carboxy-modified beads, resulting in a covalent binding of the aptamers 
to the bead surface. The amount of bound aptamer was determinant as described in 
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6.1.14, resulting in 505 pmol/mg beads. Beads modified with a random oligonucleotide 
(R47) sequence were prepared as negative control for the binding experiments. The 
sequence can be found in the aptamer list 6.2.5. The amount of immobilised aptamer for 
the negative control was determined to be 823 pmol/mg beads. The amount is higher 
than for the Lys-Apt beads which may be a result of the different length of the aptamers, 
the lysozyme aptamer is 80 nt long while the R47 is only 47 nt long. 
To detect the lysozyme bound by the aptamer modified beads via flow cytometry, the 
protein had to be labelled with a fluorescent dye. Lysozyme was labelled with the green 
fluorescing dye FITC according to a standard procedure (6.1.11). The dye to protein 
(D/P) ratio was calculated based on absorbance measurements of the protein and the 
dye. For lysozyme the D/P ratio was 0.7. 
First experiments were done with a concentration range of 0-10 µM for the FITC 
labelled lysozyme. Beads with the lysozyme aptamer and beads with the negative 
control were incubated with the target solution and kept in the dark as described in the 
methods appendix 6.1.18. After incubation the beads were directly subjected to flow 
cytometry analysis. 
 
Figure 52: Binding of lysozyme to beads modified with lysozyme aptamer and a negative control 
consisting of beads with a random oligonucleotide.  
The measured fluorescence values are higher for the beads carrying the lysozyme 
aptamer but there is also a considerable amount of unspecific binding to the negative 
control (Figure 52). This unspecific binding is believed to be caused by electrostatic 
interactions taking part between the negatively charged phosphate backbone of the 
aptamers and the positively charged protein lysozyme. Lysozyme has an isoelectric 
point (pI) of 11, which leads to a positive charge in the used binding puffer of pH 7.5. 
Interactions based on charge are crucial for aptamer binding as can be seen in Figure 53. 
The picture shows the example of the thrombin RNA aptamer binding to the positively 
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charged region (blue) of thrombin. But ionic interactions can also result in unspecific 
binding to non-target proteins with clusters of positive charge on their surface. 
 
Figure 53: Thrombin RNA aptamer binding to the positively charged region of thrombin. The single 
stranded oligonucleotide can be seen as a negatively charged polymer due to the phosphate backbone 
(129). 
Investigation of the influence of the pI on protein binding to aptamer-modified beads  
To systematically investigate the influence of the pI on unspecific binding, the 
experiments were repeated with the non target protein BSA, which has a pI of 4.7, 
resulting in a negatively charged protein molecule in the used buffer. BSA was labelled 
with FITC as described (6.1.11) to render it susceptible to flow cytometry detection. 
The D/P ratio calculated for BSA-FITC was 4.2. Both aptamer and control beads were 
than incubated with BSA-FITC solutions in a concentration range of 0-10 µM as 
described above. After incubation with fluorescently labelled proteins the beads were 
directly measured by flow cytometry. 
 
Figure 54: Comparison of lysozyme and BSA binding to beads modified with the lysozyme aptamer and a 
negative control consisting of a random oligonucleotide sequence. 
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Neither the lysozyme aptamer beads nor the negative control show binding of BSA 
(Figure 54). This appears to be logical, as the BSA and the aptamer beads both are 
negatively charged resulting in repulsion of beads and protein. To further investigate the 
effect of a proteins isoelectric point on unspecific binding to aptamer beads another 
protein, cytochrome C, was taken into account. Cytochrome C is a protein with an 
isoelectric point of 10.5 which is similar to lysozymes pI of 11. Hence it is also 
positively charged in the used buffer pH 7.4. The molecular weight of both proteins is 
also very similar, with 12.4 kDa for cytochrome C and 14.3 kDa for lysozyme. 
Cytochrome C is therefore a good model to test unspecific binding of lysozyme caused 
by charge of the molecule to the aptamer modified beads. Figure 55 shows the 
comparison of unspecific binding of cytochrome C and BSA to beads modified with the 
lysozyme aptamer and a random oligonucleotide. The binding of the positive charged 
cytochrome C is higher than that of the negatively charged BSA. There is no difference 
between cytochrome C binding to the lysozyme aptamer beads and the random 
oligonucleotide beads. The measured fluorescence values are smaller than the ones from 
lysozyme binding to the aptamer beads presented in Figure 54. 
 
Figure 55: Comparison of unspecific binding for the two negative controls BSA and cytochrome C. 
Cytochrome C is positively charged in the used buffer, resulting in higher unspecific binding to the 
negatively charged aptamer beads. 
The results of the binding studies with the lysozyme aptamer, the random 
oligonucleotide (R47) and the three proteins lysozyme, cytochrome C and BSA are 
summarized in Table 4. 
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Table 4: Summary of the binding studies with the lysozyme aptamer and all negative controls. 
Descriptions: Weak binding: “-“; binding “+”; stronger binding “+++”. 
 BSA Cytochrome C Lysozyme 
Lysozyme Aptamer - + +++ 
Random oligo (R47) - + + 
Isoelectric point (pI) 4.7 10.5 11 
 
In a further experiment it was tested if the unspecific binding of lysozyme to the 
negative control beads could be reduced by washing the beads after incubation. 
Additionally the concentration range used for incubation was expanded to 35 µM 
lysozyme. The beads were incubated with the fluorescently labelled lysozyme as 
described above and afterwards washed once with 400 µl binding buffer for 15 min. The 
samples were than measured by flow cytometry. The results are represented in Figure 
56. It can be seen that the difference between the fluorescence values of the lysozyme 
aptamer beads and the negative control is bigger than in the previous experiment 
without the additional washing step (Figure 52). There is also a saturation of the 
fluorescence values for samples with target concentrations higher than 15 µM. This 
saturation was not observed before, probably because the specific binding was overlaid 
by the unspecific binding which is now reduced after the washing step.  
 
Figure 56: Incubation of aptamer-modified beads and a negative control (R47) with lysozyme 
concentrations up to 35 µM. The samples were treated with an additional washing step. 
It can be concluded that the immobilisation of functional aptamers could be shown for 
the lysozyme aptamer and its target, although substantial unspecific binding could be 
observed. This unspecific binding is believed to be mainly caused by the target proteins 
high isoelectric point which results in a positive charged molecule that interacts with the 
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negative charged aptamer beads. Using an aptamer with a target protein exhibiting a 
near neutral or acidic pI might lead to less problems with unspecific binding. 
Beads with immobilised aptamers targeting VEGF 
After showing the successful immobilisation of functional lysozyme aptamers on beads, 
the procedure was reproduced with aptamers selected against VEGF. The aptamers 
V7t1 and Del5-1 were chosen for this purpose. The aptamers have a higher affinity and 
a more complex target than the lysozyme aptamer. 
The immobilisation of the aptamers was done according to the standard protocol 
(6.1.14), 3’-amino-modified aptamers were used for the experiments. The amount of 
immobilised aptamer was subsequently determined and resulted in 1130 pmol/mg beads 
for Del5-1 and 1212 pmol/mg beads for V7t1.  
Incubation of the aptamer beads with the fluorescently labelled target was done using 
the standard protocol described in (6.1.18) and afterwards the beads were washed once 
in binding buffer. Beads modified with a random oligonucleotide (R47) were again 
taken as negative control. The analysis of the beads by flow cytometry revealed stronger 
binding of the VEGF to the aptamer modified beads (Figure 57). The best results were 
obtained from the beads modified with the V7t1 aptamer, which shows more binding 
than the Del5-1 aptamer. The random oligonucleotide also shows increasing 
fluorescence with higher VEGF concentrations, but much lower than for the aptamer 
beads. The VEGF aptamers hence also stay functional after immobilisation on beads. 
 
Figure 57: Incubation of VEGF aptamer modified beads and a negative control with VEGF-FITC. 
The higher binding affinities of the VEGF aptamers compared to the negative control 
can also be seen clearly when comparing the histograms of the flow cytometry data. 
Figure 58 shows the overlays of the histograms for V7t1 (red, left), Del5-1 (red, right) 
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and the random oligonucleotide beads for a VEGF concentration of 200 nM. The 
aptamer histograms are shifted to the right, caused by a higher fluorescence of the 
measure beads.  
To include a negative control on the side of the target protein, the protein myoglobin 
was chosen and fluorescently labelled. Myoglobin from horse heart has a similar pI 
(7.2) as the predicted pI (7.6) of the aptamer target VEGF resulting from a calculation 
using an online tool (130). 
  
Figure 58: Histogram overlays for the aptamer-modified beads compared to the negative control. Left: 
V7t1 (red) and R47 (black). Right: Del5-1 (red) and R47 (black). VEGF concentration used for 
incubation was 200 nM. 
The V7t1 and Del5-1 aptamer beads were incubated with the same concentrations of the 
fluorescently labelled myoglobin and afterwards analysed by flow cytometry. The 
results are depicted in Figure 59 and obviously show no binding of the negative control 
myoglobin to the aptamer beads.  
 
Figure 59: Comparison of VEGF and myoglobin binding to beads modified with the VEGF aptamers 
V7t1 and Del5-1. The negative control myoglobin is not bound by the beads. 
The immobilisation of the VEGF aptamers on beads was successful, the aptamers 
proved to stay functional and able to bind their target with high affinity and specificity. 
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4.2.2.2 Direct immobilisation of aptamers on liposomes  
A direct approach using activated amino groups has been used for immobilising 
aptamers for other applications like biosensors or microarrays. A straightforward 
procedure with activated amino groups was presented by Walter et al. for coupling 
amino modified aptamers onto microarray slides (22). The method uses cyanuric 
chloride to activate the aptamers terminal amino group. The aptamer is then able to bind 
to other amino groups. The coupling reaction is illustrated in Figure 60. 
 
Figure 60: Activation of amino functionalised aptamers via cyanuric chloride and subsequent 
immobilisation on amino exhibiting surfaces (22).  
This strategy should also work for cells, as they present amino groups on the cell 
surface that are potential targets. Figure 61 shows a schematic of the intended 
immobilisation of the aptamer on the cell surface. 
 
 
Figure 61: Schematic of the direct immobilisation of amino activated aptamers on the cell surface. C: 
cyanuric chloride. 
Firstly Liposomes were used as cell models to test the direct immobilisation approach 
using cyanuric chloride in a model system with lower complexity than the cell surface. 
The liposomes or giant unilammelar vesicles (GUVs) were prepared by a lipid film 
Cell
C
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rehydration method described in 6.1.19. Two different types of lipids were used to form 
the GUVs, a standard lipid, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and a 
lipid with an amino group at the polar head, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000 (DSPE-PEG 2000 amine). 
For GUV formation the lipids were used with a ratio of 50:1 (DOPC:DSPE-PEG 2000 
Amine) to prevent steric interference between neighbouring aptamers after 




Figure 62: Structures of the lipid molecules used for vesicle formation. Top: DOPC. Bottom: DSPE-PEG 
(2000) amine. 
The produced GUVs were harvested and analysed by light microscopy to inspect their 
shape and determine their size. Afterwards, a sample containing GUVs was analysed by 
flow cytometry to assure the particles can be detected by the instrument. 
  
Figure 63: Images of GUVs prepared by film rehydration. The vesicles show a heterogenous size 
distribution. Vesicles with diameters between 10-20 µm equaling those of mammalian cells can be found 
in both pictures. 
The results show that the GUVs are formed in various sizes of up to 25 µm, which lies 
in the same range as most mammalian cells (10-20 µm) (Figure 63). The analysis by 
flow cytometry shows that GUVs are indeed detectable by the instrument (Figure 64). 
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The detectability is a prerequisite for studying the following immobilisation of 
aptamers. 
  
Figure 64: Flow cytometry analysis of GUVs. The vesicles can be detected using the same protocol and 
settings as for CHO cells. Left: FSC/SSC dotplot. Right: Autofluorescence detected by the FL1 detector 
is low and similar to CHO cells. 
The GUVs containing the amino-modified lipid were subsequently incubated with 10 
µM cyanuric chloride-activated lysozyme aptamers that were amino-modified at their 
5’-terminus and labelled with FITC at the 3’-terminus. The GUVs were incubated for 
15 min and then washed once with PBS before subjecting them to analysis by flow 
cytometry. The incubated GUVs showed a higher fluorescence than the unmodified 
ones, indicating a immobilisation of the aptamers on the GUVs (Figure 65). The large 
error bars are presumably caused by the difficult accessibility of the individual vesicles 
by the activated aptamers. The GUVs tend to cluster resulting in shielded vesicles that 
are only partly modified. This results in a high variation of the fluorescence. 
 
Figure 65: Fluorescence of the vesicles without aptamer and the ones that were incubated with cyanuric 
chloride activated and fluorescence labelled aptamer. 
Although the results from the liposome formation were promising, it was decided to 
skip the consequent optimisation approaches and move on to direct immobilisation of 
aptamers on real cells. 
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4.2.2.3 Direct immobilisation of aptamers on cells 
After successfully immobilising aptamers on beads and liposomes, the method was 
transferred to cells. CHO K1 cells were taken as model cells because of their industrial 
relevance for production of proteins and their ease of cultivation. For initial experiments 
the aptamer 264 against the Fc-fragment of IgGs was chosen. The experiments should 
demonstrate if the direct immobilisation works better than the indirect approach shown 
in section 4.2.1 and results in any detectable binding of the target. 
Firstly 5’-amino-modified 264 aptamer with a FITC label at the 3’-terminus was used 
for immobilisation to check if the aptamers can be bound covalently to the cell surface.  
CHO K1 cells were incubated with increasing concentrations of the aptamer. Two 
variants of the fluorescently labelled aptamer were compared, one with a normal amino 
modification (264AF) and one with an additional hexaethylenglycol spacer between the 
amino group and the aptamer sequence (264ASF). If the accessibility of the normal 
amino function would be somehow compromised by the aptamers fold, the use of a 
spacer could result in higher immobilisation efficiency. 
 
Figure 66: Comparison of the immobilisation of the cyanuric chloride activated aptamer 264 with an 
additional spacer and without. There is no measureable difference between both aptamers. 
Figure 66 shows that the direct immobilisation approach works but there is no difference 
between the immobilisation efficiency of the aptamer with or without the spacer. The 
amount of immobilised aptamer increases with higher concentration of the aptamer used 
for incubating the cells. The fluorescence values appear to get saturated at 
concentrations above 10 µM.  
After demonstrating the successful immobilisation of aptamers by directly coupling 
them to the cell surface, it was investigated if the aptamer is able to bind its target. 
Therefore cells were modified with different aptamer concentrations and incubated with 
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a high concentration of FITC labeled Fc-fragment (20 µM). Afterwards the cells were 
analysed by flow cytometry to detect the fluorescence from the cell-bound Fc-fragment.  
 
Figure 67: Binding of fluorescence labelled Fc fragment to cells modified with cyanuric chloride 
activated aptamers. Cells were incubated with various concentrations of the activated aptamer and 
afterwards incubated with 20 µM Fc-fragment.  
Figure 67 shows that no significant binding of the Fc-fragment to the modified cells can 
be detected. These results and the failed attempt using the indirect immobilisation 
approach show that the problem is probably related to the aptamer 264. The 
thermophoresis experiments support this assumption as they reveal a low affinity of the 
aptamer towards the Fc-fragment (4.2.1.2). To prove that the strategy of immobilising 
functional aptamers on living cells is in principle possible, the model system was 
changed to another aptamer-target system. 
For further experiments the aptamer against lysozyme (Lys-Apt) was chosen, because it 
proved to stay functional on beads (4.2.2.1) and its target molecule, in contrast to the 
Fc-fragment, is easily accessible in high amounts. 
The cells were modified with the cyanuric chloride-activated lysozyme aptamer (5’-
amino group) by incubating the cells with 10 µM of the activated aptamer as described 
in appendix 6.1.16. To check for unspecific binding of the positively charged lysozyme 
to the aptamer, the protein cytochrome C, which has a similar pI, was used as a negative 
control. The cytochrome C was also labelled with the fluorescent dye FITC. 
Unmodified CHO K1 cells were employed as additional negative controls and incubated 
with FITC-labelled lysozyme and cytochrome C. The cells were all analysed by flow 
cytometry to detect the fluorescence of the cell bound proteins. 
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Figure 68: Incubation of lysozyme aptamer-modified and unmodified cells with lysozyme and the 
negative control cytochrome C. High concentrations of lysozyme are bound by aptamer-modified cells 
but not the negative controls. 
There are high fluorescence values for the Lys-Apt modified cells for lysozyme 
concentrations above 15 µM compared to the negative controls (Figure 68). 
To demonstrate the feasibility of the approach for further aptamer-target pairs, 
immobilisation experiments were performed using two aptamers against VEGF. The 
aptamers V7t1 and Del5-1 also proved to stay functional after immobilisation on beads 
after direct coupling (4.2.2.1). The aptamer V7t1 was also capable of binding its target 
after immobilisation via biotin on streptavidin coated beads (4.2.1.1). 
After standard activation of the 3’-amino groups by cyanuric chloride 10 µM of the 
aptamers were used for incubating 10
6
 CHO K1 cells. The cells with immobilised 
aptamer were then incubated with FITC labelled VEGF and myoglobin in a 
concentration range of 100-1200 nM. Myoglobin was used as a negative control 
because it has a pI similar to VEGF.  
 
Figure 69: Flow cytometry results of aptamer-modified CHO cells incubated with VEGF-FITC and the 
negative control myoglobin-FITC. 
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Figure 69 shows that the aptamer-modified cells bind the aptamer target VEGF but not 
the negative control myoglobin. The results demonstrate that it is possible to immobilise 
functional aptamers on the cell surface by direct coupling after cynanuric chloride 
activation. In order to develop assays based on this finding it is a prerequisite to 
investigate the effects of the cell surface modification on the cells viability and growth. 
This topic is described in the following section. 
 
4.2.2.4 Cultivation of modified cells – effects on cell viability and growth 
The immobilisation of cyanuric chloride-activated aptamers on the cell surface works 
by covalent binding to molecules present on the exterior cell membrane. The 
modification might interfere with the function of these molecules which could 
potentially be harmful to the cell. With regard to the development of assays for living 
cells it is therefore necessary to investigate the effects of the immobilisation procedure 
on the cells viability and growth. 
The immobilisation via biotin-streptavidin (91) is known to have no negative effects 
and cells have succesfully been cultured after modification. 
To investigate the effect of the direct immobilisation approach with cyanuric chloride-
activated aptamers, a comparative cultivation of modified and unmodified CHO cells 
was monitored over a period of 120 hours. The cells were incubated with fluorescently 
labelled aptamers activated by the standard cyanuric chloride method (6.1.16). The 
cultivation was done in 125 ml shake flasks, which were filled with 21 ml starting 
culture of a cell density of 400.000 cells/ml. The shake flasks were wrapped in 
aluminium foil to prevent the cultures from light. Samples were taken three times per 
day to analyse cell density and viability by CEDEX and levels of glucose and lactate 
with a YSI analyser. In addition the fluorescence of the cells was analysed by flow 
cytometry once a day. 
Figure 70 shows the growth and viability of the two cell populations during cultivation. 
There is nearly no difference between the cultivations. The modified cells reach even a 
higher cell density than the unmodified cells. 
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Figure 70: Comparative cultivation of aptamer-modified and unmodified cells. Left: Cell density and 
viability. Right: Glucose and lactate values during cultivation. No negative effect of the modification on 
cell viability and growth could be observed. 
The metabolic behaviour of the two populations is also very similar as can be seen by 
the course of the glucose and lactate graphs in Figure 71. The analysis of the cell 
fluorescence by flow cytometry shows a higher value for the modified cells with the 
fluorescently labelled aptamer, but only for the sample taken immediately after 
inoculation (Figure 71). The samples of the following days all show the same 
fluorescence intensity as the unmodified cells, which exhibit common autofluorescence. 
The decay of the signal is not surprising as the cells continue to divide and hence dilute 
the amount of immobilised aptamers per cell. In addition it is possible that the 
fluorescence dye is bleaching out over time, although it was tried to prevent this by 
mantling the flasks with foil. 
 
Figure 71: Analysis of cell fluorescence during the cultivation. As expected the fluorescence declines 
with time. Already after day one the fluorescence of the modified cells falls to the value caused by 
autofluorescence of the unmodified cells. 
In summary no negative effects of the direct immobilisation procedure could be 
observed. The approach thus seems to be applicable for modification of living cells that 
can subsequently be cultured or further manipulated. 
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4.2.2.5 Investigation on a cell based aptamer-sandwich assay for VEGF detection 
All experiments presented so far focused on the proof of principle that bead or cell 
immobilised aptamers are able to bind their target and that this binding can be detected 
by flow cytometry. Fluorescently labelled target proteins were used for this purpose. 
For the potential application of cell immobilized aptamers in a cell screening assay, 
another detection approach has to be developed. With regard to screening cells for the 
ability to produce a certain protein in high amounts, the protein itself will not be 
fluorescent like the artificially labelled proteins used for the experiments shown above. 
In order to detect these proteins which are captured by the aptamers on the cell surface, 
a sandwich assay containing another detection agent is conceivable. The following 
section presents the experiments performed with bead and cell immobilised aptamers to 
show a proof of principle of such an aptamer based sandwich assay. The principle 
composition of the assay is presented in Figure 72. The immobilised aptamer binds the 




Figure 72: Schematic drawing of the aptamer-based sandwich assay. Immobilised aptamers bind the 
target which is than detected by a second labelled aptamer. 
Initial experiments were again carried out using aptamers immobilised on beads. The 
VEGF aptamer V7t1 was bound to polystyrol beads, because it appeared superior to the 
other tested VEGF aptamer Del5-1. “Bioplex 200 COOH Beads 24” from Biorad were 
used for the experiments and modified according to the manufacturer (6.1.20). In 
summary, 3’-amino-modified aptamers were coupled to the carboxyl-groups on the 
beads surface via EDC coupling chemistry. 5000 of the aptamer modified beads were 
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negative control myoglobin for 30 min in a rotator. Afterwards the beads were pelleted 
by centrifugation (4 min, 14000 g) and the supernatant discarded. The beads were 
finally resuspended in 50 µl of the labelled detection aptamer and analysed with a 
Biorad Bioplex 200 system, which works by the same principle as a flow cytometer but 
is tailored to bead analysis. The detection aptamers were labelled with the fluorescent 
protein R-phycoerythrin (R-PE) as recommended by the manufacturer (6.1.11) and 
alternatively with the fluorescent dye Cy3 which should also be compatible with the 
instruments laser and detector settings. Cy3 was included as alternative label because it 
is much smaller (0.8 kDa) than the fluorescent protein R-PE (240 kDa) which might 
avoid steric hindrance of the aptamer during target binding. Both VEGF aptamers V7t1 
and Del5-1 were tested as detection aptamers in the sandwich assay. 
 
Figure 73: Aptamer-based sandwich assay on beads. The labels indicate the used detection aptamer and 
protein. Data presents median values without error bars. 
Figure 73 gives an overview of the tested aptamer combinations that were used to detect 
the bound target protein VEGF. The results also include myoglobin as a negative 
control that should not be bound by the bead immobilised aptamer or by the second 
detection aptamer. The data meets the expectations quite well. All sandwich assays with 
the target protein VEGF give higher fluorescence signals than the samples containing 
the negative control myoglobin. The aptamer V7t1 again exhibits a stronger target 
binding than Del5-1. For the R-PE labelled aptamers there appears to be low unspecific 
binding to the myoglobin incubated beads whereas the corresponding samples with Cy3 
label show signals close to zero. 
To further assure the obtained result, the test was repeated and expanded with a negative 
control on the aptamer site of the assay. The aptamers 264 and 266 which do not bind 
VEGF were chosen for this purpose and used as 3’-amino modified versions. All 
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detection aptamers were used with a Cy3 label this time, which proved to work 
successfully in the previous analysis. The preparation of the beads was done as 
described in the appendix 6.1.20. Finally the samples were analysed on a Biorad 
MagPix instrument to measure the fluorescence intensities of the respective beads. 
Figure 74 shows the obtained mean values of all samples. The labels explicitly describe 
the used components of the sandwich assay in the following order: The bead 
immobilised aptamer is named first, than the protein and at last the detection aptamer. 
 
Figure 74: Systematic investigation on specificity of the bead-based aptamer sandwich assay. All 
detection aptamers are labelled with the fluorescence dye Cy3. Data presents mean values. 
It can be seen that the sandwich assay preparations which contain the VEGF aptamer 
V7t1 work best and show the highest fluorescence values. The assay also works with 
two identical aptamers because VEGF is a homodimer and presents two identical 
binding sites. Those including the aptamer Del5-1 as detection aptamer are however 
yielding lower signals than those with V7t1. The samples which contain one or more 
negative control elements as parts of the sandwich assay show considerably lower 
fluorescence values except for the sample 264-VEGF-V7t1. This preparation yields a 
fairly high fluorescence although the immobilised 264 should not bind the VEGF. A 
possible explanation for this finding is a general unspecific binding of VEGF to the 
oligonucleotide exposing bead surface and its subsequent detection by the highly affine 
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V7t1 aptamer. Although the systematic investigation of specificity and affinity of the 
aptamer sandwich assay is not flawless, the results are quite promising. The 
development of a sandwich based assay for protein detection on particles in a flow 
cytometer seems feasible. By optimising sample preparation and washing procedures it 
could be tested if the unspecific binding can be reduced or eliminated. 
The next step was the transfer of the sandwich assay from beads to the surface of real 
cells. CHO cells were chosen again as model system for this approach. Immobilisation 
of aptamers was achieved by the cyanuric chloride activation protocol described above 
6.1.16. The 3’-amino-modified aptamer V7t1 was used for immobilisation on the cells 
and modified cells were subsequently incubated with a concentration series of 
unlabelled VEGF for 30 min. After incubation, the cells were centrifuged and 
supernatant was discarded. The cell pellet was resuspended in Cy3-labelled V7t1 
aptamer and incubated for further 30 min. After centrifugation the pellet was again 
resupended in aptamer binding buffer and analysed by flow cytometry to detect the 
bound aptamers. Figure 75 shows the results of the aptamer-modified cells compared to 
a negative control with no immobilised aptamers on the cell surface. The data reveals no 
difference in signal intensity for the cell-based sandwich approach and the negative 
control. The fluorescence intensities are low and based on the data no binding is 
observable. This might be caused by problems with the sandwich assay and the 
detection aptamer which has to bind the target in the complex environment of the cell 
surface.  
 
Figure 75: Analysis of modified cells used for a aptamer sandwich assay. The modified cells were 
incubated with increasing VEGF concentrations and subsequently incubated with a detection aptamer. No 
binding can be detected. 
It can be concluded that the aptamer sandwich assay depicted in Figure 72 works with 
limitations on aptamer modified beads. The successful transfer of the assay to cells 
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could not be achieved but the approach presents a good starting point for further 




5 Conclusions and outlook 
The aim of this work was the investigation of aptamer applications for flow cytometry 
assays. These investigations should be performed by the development and analysis of 
adequate model systems. Two projects were carried out to explore the feasibility of 
aptamer-based assays. The first aimed at using aptamers as specific recognition reagents 
for labelling cell surface molecules in flow cytometry analysis. This task is typically 
performed by antibodies which have been used for decades as stains in flow cytometry. 
Aptamers could complement antibodies in various assays or even substitute them by 
offering higher storage stability at reduced costs. The second project was intended to 
investigate the possibility of an aptamer-based screening assay that employs flow 
cytometry and cell sorting to select cells with a high protein secretion. This application 
is of particular importance for the production of biopharmaceuticals which gain more 
and more importance and are needed to treat increasing numbers of patients in the 
ageing societies.  
 
Part 1: Aptamers as stains for cell surface proteins in flow cytometry  
A model system comprised of the aptamer TD05 was used to study the application of 
aptamers as cell surface stains for flow cytometry. The functionality and specificity of 
fluorescently labelled TD05 was verified in a protein microarray binding assay with the 
target protein IgM and other non-target proteins (4.1.1). The aptamer only showed 
binding to the IgM but not to the negative controls present in the experiment. Further 
negative controls were introduced to assure that the binding to IgM is specific and does 
not result from the oligonucleotide nature of the aptamer molecule. A random 
oligonucleotide sequence and a pool of ~10
12
 different sequences were used for this 
purpose and compared to the aptamer in the above mentioned microarray assay. Both 
negative controls showed no binding to the target molecule, proving the specificity of 
the aptamer-target binding for TD05. The investigation was then transferred to the flow 
cytometry format. Firstly by analysing beads modified with the target molecule IgM, 
which were incubated with the fluorescently labelled aptamer and subsequently 
analysed. By comparing the binding of TD05 to IgM beads with binding to beads 
modified with the non-target protein BSA, it could be shown that the aptamer-target 
binding can be detected by flow cytometry. To verify the binding of TD05 to IgM 
molecules on the surface of the Ramos target cells, microscopy analysis of stained cells 
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were performed. The aptamer was able to stain Ramos cells, whereas CHO cells were 
not stained after incubation with TD05. Cultured Ramos cells were subsequently 
incubated with TD05 and analysed by flow cytometry (4.1.4). The results show strong 
binding to the target cells. CHO cells and more closely related CCRF-CEM cells were 
used as negative controls to exclude the possibility of unspecific binding to common 
cell surface structures. None of the negative controls was bound by the aptamer. The 
random sequence and oligonucleotide pool were also used to further assure the specific 
binding of TD05 to Ramos cells. The observed binding for the controls was very low 
and the marginal staining is believed to result from unspecific binding to cell surface 
molecules. In order to confirm the proteinogenic nature of the cell surface target another 
experiment was conceived in which Ramos cells were treated with a proteinase to 
partially digest the proteins on the cell surface. When compared to untreated cells, the 
proteinase treated cells showed fewer binding of the aptamer thereby supporting the 
hypothesis of IgM as the target molecule. 
The aptamer TD05 was also used to fabricate a new kind of detection agent by coupling 
the aptamer to fluorescent nanoparticles called quantum dots (4.1.5). The conjugates 
were afterwards characterised in binding studies by using protein microarrays as 
described above for TD05 labelled with a standard organic dye. The conjugates proved 
to be able to recognise IgM and showed no binding to the protein negative controls. The 
conjugates were subsequently used to label Ramos cells and analyse the staining by 
flow cytometry. The conjugates failed to show specific binding to the target cells. The 
unspecific binding to the control cells is believed to result from non-specific cellular 
uptake of the aptamer-QD conjugates. The use of aptamer functionalised QDs still 
presents a promising alternative to established antibody-based staining in flow 
cytometry. Especially with regard to multicolour applications, QDs offer advantages 
because of their good excitability and their narrow emission spectra. Further 
optimisation of the application protocols with regard to incubation times and washing 
steps is needed to find conditions enabling the specific staining of cells with this novel 
reagents. 
 
Part 2: Immobilisation of aptamers on the cell surface and their characterisation by flow 
cytometry 
In the second part of this thesis, the investigations focused on the immobilisation of 
functional aptamers on the cell surface with the ultimate goal of demonstrating a proof 
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of principle for a flow cytometry screening of secretory cells used in biopharmaceutical 
production. Starting from scratch the immobilisation of aptamers was first done on bead 
microspheres, which served as basic models for cells. Different aptamers were tested for 
their ability to still recognize their target after immobilisation. The immobilisation was 
performed by two different approaches. Immobilisation of biotinylated aptamers on 
streptavidin beads did not yield functional aptamers in all experiments. For direct 
immobilisation on beads the results were more promising. Whether or not an aptamer 
stays functional after immobilisation depends on its fold and the functionality has to be 
tested and confirmed for each aptamer individually, before further applications can be 
developed. 
The indirect immobilisation of aptamers on the cell surface via a streptavidin bridge was 
shown step by step for the aptamer 264 which was selected against the Fc-fragment of 
human IgGs (4.2.1.2). Although the immobilisation was successful, the aptamer was not 
functional on the surface and it could not be shown to bind its target. Various 
approaches were investigated to solve this problem but later performed binding studies 
by MST revealed a very low affinity of the aptamer-target interaction in solution. After 
immobilisation the affinity will probably even be lower due to sterical impairment. The 
low affinity of the target is problematic because higher Fc-fragment concentrations also 
lead to increased unspecific binding to the cell surface. The failure of this aptamer-
target system was a huge drawback for the project because it could have been used to 
screen antibody producing cells with the cell surface capture assay. However, by using a 
different aptamer-target system, it could be shown that an aptamer against VEGF was 
still able to bind its target after immobilisation on the cell by the indirect approach 
(4.2.1.3). Flow cytometry measurements showed increased binding of the fluorescently 
labelled protein which was incubated with the cells at different concentrations.  
Furthermore it was demonstrated that the immobilisation of aptamers by the indirect 
approach via a streptavidin bridge is also feasible for other cells than CHO. The 
biotechnologically important yeast P. Pastoris was successfully modified with the 
aptamer matrix and a comparative cultivation showed no adverse effects on the growth 
of the cells. 
 
To circumvent the tedious multi step method of modification required for the indirect 
immobilisation, a new method of immobilisation was developed. Amino-modified 
aptamers, which were activated via cyanuric chloride, were used for direct 
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immobilisation of aptamers on the cell surface (4.2.2.3). The approach is based on the 
binding of the activated amino group to other amino groups on the cell surface and 
proved to work well for a model system of amino-exposing liposomes and CHO cells. 
Aptamers targeting VEGF also stayed functional after immobilisation on cells and were 
able to bind their target proteins, which could be shown by flow cytometry.  
In order to be used in later cell sorting applications, it is an absolute prerequisite that the 
used immobilisation procedure has no negative effect on the cells viability and growth. 
This work demonstrated the successful cultivation of cells directly modified with 
cyanuric chloride activated aptamers (4.2.2.4). The results indicate that cells can be 
further cultured and expanded for further screening after this modification. 
Finally, a possible detection method for a later application in screening for high 
secreting cells was investigated. While all previous investigations were performed with 
fluorescently labelled target proteins, the next step involved the evaluation of an 
aptamer based sandwich detection assay (4.2.2.5). In a final application the amount of 
secreted protein captured by the immobilised aptamers has to be determined by either 
using a fluorophore-quencher system or a second detection aptamer. It could be shown 
that a sandwich detection assay works quite well for bead immobilised aptamers, 
although some issues with unspecific binding to the used beads could be found. 
However, when transferred to the cell surface the detection by a second aptamer failed 
to work. This might be because of the more complex environment found on the cell 
surface which leads to sterical hindrance of the assay components. The unspecific 
binding, which was observed in the bead-based investigations is a problem often 
encountered in the development of aptamer applications and presents a major hurdle for 
the use of aptamers in analytical assays. Unspecific binding of aptamers can in general 
occur to positively charged surfaces due to the aptamers negatively charged phosphate 
groups and to other oligonucleotide structures by base pairing and partial hybridisation. 
For further development of the assay it would be useful to develop a target release 
system consisting of a secreting cell with a product that can be bound reliably by a well 
characterised aptamer. This release system could then be studied in detail for the 
development of a functioning detection system and a proof of principle for the isolation 




6  Appendices 
 
6.1 Methods 
6.1.1 Preparation and analysis of reverse phase protein microarrays for 
analysis of fluorescently labelled aptamers and aptamer-quantum dot 
conjugates 
The protein microarrays were fabricated by spotting protein solutions on aldehyd 
functionalized glass chips (VSS-25, Vantage Silylated Aldehyde Slides, CEL, USA) A 
contact free spotter was used for this purpose GeSiM (Modell: NanoPlotter 2.1). Eight 
droplets with a volume of approximately 0.2 nl were deposited per spot. The spotting 
process was performed at room temperature and a humidity of 70 %. PBS was used as 
spotting buffer. The chips were incubated for further 30 min under this conditions and 
then dried for 30 min at room temperature at atmospheric humidity. 
The following samples were spotted: 
 Proteinsolution Spotted concentration [mg/ml] 
Negative 
controls 
BSA 1 - - - 
FCS 1 - - - 
(PFEI)  1 - - - 
Target protein IgM 1 0,5 0,1 0,01 
 
The schematic pattern of a spotted microarray block is shown in Figure 76. The four 
concentrations of IgM are spotted on the left, followed by a gap of three columns and 
the negative control proteins. For the analysis of the aptamer quantum dots only BSA 





Figure 76: Schematic pattern of a plotted microarray block (left). A fully spotted chip consisted of 16 of 
these blocks (right). 1. Konz.: 1 mg/ml; 2. Konz.: 0.5 mg/ml; 3. Konz.: 0.1 mg/ml; 4. Konz.: 0.01 mg/ml.  
 
The microarrays were blocked with a solution of BSA in PBS (1% w/v) for 30 minutes 
and afterwards washed with PBS for 5 min and two times with H2O for 1 min. Next the 
rubber support was applied to create isolated chambers for each block on the chip. 50 µl 
of the aptamer or aptamer-QD conjugate in TD05 binding buffer were applied into each 
chamber. The microarray was incubated overnight at RT and then each chamber washed 
three times for 10 min with 100 µl binding buffer. After taking of the rubber support the 
chips were washed again three times for 10 min in binding buffer. The chips were 
finally dried by centrifugation or compressed air and scanned by using a dedicated 
fluorescence scanner. 
The used scanner was a GenePix®4000B (Axon Instruments, USA). The chips were 
scanned with the preinstalled settings for the dye. The aptamer-QD655 chips were 
scanned with the settings for Cy5 which are suitable for excitation and detection of QDs 
with 655 nm emission maximum. The laser power was 100 % and different gains were 
used as indicated for the results. 
The obtained images were analysed with the software GenePixPro 6.0 (Molecular 
Devices, USA). The presented relative signal intensity is calculated by substracting the 
measured background mean (BM) from the signal mean (SM) of the respective spot. 
Error bars show the standard error of the value calculated on the basis of all replicates. 
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6.1.2 Microscopic analysis of aptamer-stained Ramos cells 
The samples for the microscopic analysis of aptamer-stained Ramos cells were prepared 
as follows: 
- 1 ml cells per sample were taken from culture and washed once with 1 ml PBS. 
The washing was done by centrifuging the cells in Eppendorf tubes for 5 min at 
200 g and resuspending them in PBS 
- Afterwards the cells were washed 1 x with TD05 binding buffer and 1x with 
binding buffer containing 2 % FCS 
- Cells were centrifuged again and resuspended in 100 µl aptamer in binding 
buffer with 2% FCS 
- The samples were incubated for 45 min 
- Afterwards the samples were washed 1 x with binding buffer with 2 % FCS and 
1 x with binding buffer 
- The cell pellets were stored on ice until analysis (max 1 h) 
- For analysis the cells were resuspended in 50 µl binding buffer and applied onto 
a microscopic slide 
- The fluorescence was analysed with an Olympus IX 50 fluorescence microscope 
using the NG filter (Exc. 530-550; Em. BA 590) which filters for Cy3 
fluorescence 
6.1.3 Protein coupling to tosyl-activated beads 
The proteins IgM and BSA were coupled to tosyl-activated beads (Dynabeads-280-
Tosyl, Invitrogen, USA) according to the suppliers protocol. Washing fractions were 
collected from the process to calculate the amount of coupled protein. The subsequent 
analysis of the solution at 280 nm using a Nano Drop ND-1000 spectrophotometer 
revealed a disturbance of the protein measurement which made it impossible to 
calculate the protein amount on the beads. The disturbance might be caused by 
substances leaching out of the beads. 
For the flow cytometry analysis, 1 µl of the modified bead solution were incubated with 
100 µl of aptamer in binding buffer for 60 min at RT in the dark. Afterwards the beads 
were separated from the supernatant using a magnetic stand, resuspended in 300 µl 
binding buffer and analysed by flow cytometry. 
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6.1.4 Staining of cells with fluorescently labelled aptamers for flow 
cytometry analysis 
The sample preparation was as follows (washing is done by resupending the cell pellet 
in buffer and then centrifugating it for 5 min, 200 g): 
- Cells were washed 1 x with PBS  
- Cells were washed 1 x with TD05 binding buffer 
- Cells were split into Eppendorf tubes at 1 ml with ~106 cells/ml 
- Cells were pelleted in the Eppendorf tubes by centrifugation as described above 
- Cell pellets were resuspended in 100 µl of the aptamer-FITC solution in binding 
buffer with respective concentration. 
- Incubation for 60 min on an eppendorf tube shaker in the dark at RT 
- Centrifugation as above, discarding the supernatant 
- The pellets were kept on ice in the dark until analysis 
- For analysis the pellets were resupended in 300 µl binding buffer and subjected 
to flow cytometry 
All flow cytometry data was analysed using the software WINMDI 2.8 (J. Trotter, 
Scrips Institute, USA) to obtain mean fluorescence intensities and additional data for the 
cells. 
6.1.5 Proteinase K treatment of Ramos cells 
Ramos cells were taken from culture, diluted to a concentration of 5*10
6
 cells/ml with 
PBS and 3 ml of the suspension centrifuged for 5 min at 200 g. The supernatant was 
discarded and the cell pellet resuspended in 3 ml proteinase K (0.1 mg/ml) in PBS. The 
cells were incubated for 11 min at 37 °C in an eppendorf tube shaker at 450 rpm. 
Afterwards the reaction was quenched/stopped with 200 µl FCS (1 mg/ml) and the 
tubes kept on ice for a few minutes. The cells were then washed with 6 ml binding 
buffer and centrifuged for 5 min at 200 g at RT. After discarding the supernatant the 
pellet was resuspended in 16 ml binding buffer. The cells were then subjected to the 
standard aptamer labelling protocol (6.1.4).  
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6.1.6 Fabrication of aptamer-QD conjugates 
The fabrication and characterisation of the aptamer-QD conjugates was done in 
cooperation with Annette Müller during the experimental work of her Bachelor thesis in 
Q1/2012. The conjugates were prepared with a 8 µM stock solution of carboxyl 
modified QD655 (Invitrogen, USA). 6.25 µl of the stock solution were mixed with 50 
µl 10 mM SBB (pH 7.4) and 12 µl aptamer solution (5’-amino modified 150 µM). 
1.425 µl 1-Ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (EDC) 
(10 mg/ml,) prepared fresh in ddH2O were added to the solution. The reaction was 
incubated for 3 h at RT while shaking on an eppendorf tube shaker at 400 rpm. 
Afterwards the conjugates were washed eight times by adding 200 µl 50 mM SBB 
(pH 8.3) and centrifugating for 2.5 min and 4000 g at 25 °C in a 50 kDA MWCO spin 
column. After the last washing step the supernatant was transferred into a new tube. 
30 µl 10 mM SBB (pH 7.4) were added. 
6.1.7 Staining of cells with aptamers and aptamer-QD conjugates for flow 
cytometry 
Cells were taken from culture and diluted with PBS to yield a cell concentration of 
1*10
6
 cells/ml. Samples of 1 ml were transferred to reaction tubes. Cells were then 
washed by centrifugation (200 g for 5 min) 1x with PBS, 1x with aptamer binding 
buffer and finally resuspended in 100 µl of the respective concentration of labelled 
aptamer. The samples were incubated for 60 min at RT on an Eppendorf tube shaker at 
450 rpm. After incubation, the cells were pelleted in a centrifuge (200 g for 5 min), the 
supernatant was discarded and the pellets kept on ice until analysis (max 1 h). For 
analysis the pellets were resuspended in 300 µl aptamer binding buffer and measured in 
a flow cytometer. After gating the living cells via FSC/SSC the fluorescence was 
analysed in the respective detector (FITC: FL1; Cy3: FL2; QD655: FL3). 
6.1.8 Micro BCA assay 
The micro BCA assay was obtained from Thermo Fisher Scientific and used according 
to the manufacturer. The assay was used to determine the concentration of VEGF after 
purification and after labelling with FITC. 
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6.1.9 Cell cultivations 
Ramos and CCRF-CEM cells were obtained from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). All information 
on these cell lines was obtained from the DSMZ website (www.dsmz.de, accessed on 
01.07.2011) 
Ramos cells (DSMZ ACC No. 603) 
Species: human (Homo sapiens) 
Cell type: Burkitt lymphoma  
Origin: established from the ascitic fluid of a 3-year-old boy with American-type 
Burkitt lymphoma in 1972; cells were described to be EBV-negative but EBV 
infectible, to carry the (8;14) translocation and TP53 mutations  
 
Morphology: round cells growing singly or in clumps in suspension  
Medium: 80% RPMI 1640 + 20% h.i. FBS  
Subculture: split culture 1:2 to 1:3 twice a week; seed out at ca. 0.8 x 10
6
 cells/ml; 




CCRF-CEM cells (DSMZ ACC No. 240) 
Species: human (Homo sapiens) 
Cell type: T cell leukemia  
Origin: established from the peripheral blood of a 3-year-old Caucasian girl with acute 
lymphoblastic leukemia (ALL) at relapse (terminal) in 1964 (first continuous human T-
ALL cell line) 
Morphology: round cells growing singly in suspension and as adherent epitheloid cells 
forming a monolayer 
Medium: 90% RPMI 1640 + 10% h.i. FBS  
Subculture: split saturated culture every 2-4 days; cells form monolayers until 
confluence and will then go into suspension; after transfer of suspension cells to a new 
flask, a new monolayer will develop; it may be necessary to use trypsin/EDTA or 






CHO K1 cells 
Species: Chinese hamster (Cricetulus griseus) 
Cell type: ovary 
Medium: Miltenyi CHO MACS with 8 mM glutamine  
Subculture: split culture every 3-4 days; 
 
Pichia Pastoris GS 115 
The Pichia pastoris host strain GS115 has a mutation in the histidinol dehydrogenase 
gene (his4) that prevents them from synthesising histidine. Cultures were prepared fresh 
from frozen stocks provided by Maria Zahid (126). 
The cultivation is described in 4.2.1.4 and was done in BMGY media (buffered 
glycerol-complex medium), which consists of 1 % (w/v) yeast extract, 2 % (w/v) 
peptone, 100 mM potassium phosphate, 1.34 % (w/v) YNB (yeast nitrogen base), 4 x 
10
-5
 % (w/v) biotin, 0.004 % histidine (w/v) and 1 % glycerol with a pH of 6.0. 
 
6.1.10 Production of VEGF using a recombinant E.coli strain 
The human vascular endothelial growth factor (VEGF165) was produced by culturing a 
recombinant E.coli strain and purifying the protein from inclusion bodies formed by the 
bacterium. The strain E. coli BL21DE3, transformed with the pET16b-VEGF165-Xa-
His vector, was obtained from Maren Lönne (co-worker, Institut für Technische 
Chemie) and used for this purpose. A map of the vector is shown in Figure 77. The 





The sequence starts with a 20 amino acid long section carrying the His-tag followed by 




Figure 77: Map of the vector pET16b-VEGF165-Xa-His, which was used to produce recombinant VEGF 
with an E.coli culture. Image obtained from Maren Lönne, co-worker, Institut für Technische Chemie.  
The cultivation was performed at 37°C and 150 rpm in LB-Medium containing 
carbenicillin (150 µg/ml). The induction was performed using a 200 mM IPTG stock 
solution after the culture reached OD600 of 0.5 resulting in a final IPTG concentration of 
1 mM. The cells were cultivated for further 4 hours and harvested by centrifugation at 
6000g. The cell pellet was stored at -20°C until the downstream process. 
The cell disruption and cleaning of the inclusion bodies was performed according to 
Siemeister et al. (131) the solubilisation of VEGF from the inclusion bodies was 
performed according to Pizarro et al. (132). The subsequent purification of VEGF was 
done according to a method developed by Maren Lönne in her ongoing dissertation at 
the Institute of Technical Chemistry. The process consists of an ion-exchange 
chromatography followed by dialysis and a heparin affinity chromatography.  
Ion exchange chromatography 
After solubilisation of the inclusion bodies at pH 9.8 the partially negatively charged 
VEGF was bound to a Sartobind Q75 membran adsorber and separated from differently 
charged proteins by washing with 25 mM CHES, 1mM Urea, 100 mM L-Arg pH 9. 
After elution using 25 mM HEPES, 1 mM Urea, 1 M NaCl, pH 7.1, the VEGF 
containing fractions are collected and later dialysed using dialysis tubes with 6-8 kDa 
cut off (Spectrum labatories Inc., USA). The respective chromatogram of the ion 
exchange chromatography is shown in Figure 78. The dialysis is performed against PBS 
pH 8 (at least 100x volume of the sample) for at least 4 hours at 4°C.  
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Figure 78: Chromatogram of the IEX chromatography for purifying VEGF. The VEGF is eluted using a 
salt gradient. The VEGF containing fractions 10 and 11 are taken for further downstream steps. 
Heparin affinity chromatography 
Afterwards the sample is subjected to a heparin affinity chromatography using a HiTrap 
Heparin column 1 ml (GE Life Science). After sample loading the column is rinsed with 
15 ml PBS pH 8. The VEGF is eluted by using PBS with 2 M NaCl pH 8. The 
respective chromatogram is shown in Figure 79. The VEGF containing fractions are 
stored at -20 °C until further use. The VEGF concentration was measured by BCA 
assay. 
 
Figure 79: Chromatogram of the heparin affinity seperation for purifying VEGF. The VEGF is eluted 
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6.1.11 Labeling of aptamers with R-phycoerythrin (R-PE) 
For the experiments with the Biorad Bioplex 200, aptamers were labeled with the 
fluorescent protein R-PE using a R-PE rapid conjugation kit (LYNX, USA). The 
conjugation was performed according to the suppliers instructions. In summary, a third 
of the volume contained in the ready to use R-PE kit was used to label 695 pmol of 
aptamer. The reaction mixture was incubated for three hours at RT. After incubation 2 
µl of quencher was added and the solution was left for 30 min before further use.  
6.1.12 Labeling of proteins with fluorescein isothiocyanate (FITC) 
The proteins lysozyme (Lys), bovine serum albumin (BSA), cytochrome C (Cyt-C) and 
myoglobin (Myo) were obtained from Sigma Aldrich, Germany. The human VEGF165, 
was produced in-house using a recombinant E. coli strain and purified according to 
section 6.1.10. The proteins were labelled with FITC (Sigma Aldrich, Germany) 
according to the manufacturer. The dye to protein ratio (D/P) was assessed by 




6.1.13 Immobilisation of aptamers on streptavidin-modified beads 
Dynabeads M-280 streptavidin from Invitrogen, USA, were used for the experiments. 
The modification with biotin-labelled aptamers was performed according to the product 
information sheet (http://www.lifetechnologies.com/order/catalog/product/11205D; 
accessed on 20.01.2014):  
The used binding and washing (B&W) buffer is prepared double concentrated (2x): 
10 mM Tris-HCl pH 7.5 
1 mM EDTA 
2 M NaCl 
Modification procedure: 
1. Beads are diluted to 1 µg/µl by adding 1 µl of the stock solution to 99 µl B&W 
(2x). 
2. Add 100 µl DNA solution (in dd H2O). 
Appendices 86 
3. The solution was incubated for 15 min in a rotator. 
4. The beads were separated from the solution using a magnetic stand.  
5. The beads were washed 3x with 200 µl 1x B&W buffer for 10 min in a rotator. 
6. Finally the beads are resuspended in PBS and stored at -4°C until further use. 
 
6.1.14 Immobilisation of aptamers on carboxyl-modified magnetic beads 
Terminal amino-modified aptamers were coupled to carboxyl-modified magnetic beads 
(BioMag® Maxi Carboxyl, Bangs Laboratories Inc., Fishers, IN, USA) utilising EDC 
coupling chemistry. All coupling and washing steps were performed in Eppendorf tubes 
under rotation of 20 rpm in a rotator. Magnetic separations were performed manually 
utilising a magnetic stand.  
Per experiment, 100 µl of the magnetic particle suspension (20 mg/ml) were washed 
with 100 µl 25 mM MES pH 6 for 10 min twice. Afterwards, 100 µl of 25 µM aptamer 
solution in MES was added and incubated for 30 min at room temperature. EDC 
solution (10 mg/mL) was prepared in ice-cold MES immediately before use and 30 µl 
of this solution were added to the magnetic beads. The coupling was performed at 4°C 
overnight. To remove unbound aptamer, the aptamer-modified magnetic beads were 
washed with 100 µl of 50 mM Tris pH 7.4 for 10 min four-times. Finally, the magnetic 
beads were washed with binding buffer for 20 min twice, transferred to fresh binding 
buffer and stored at 4 °C. The amount of immobilized aptamer was calculated via 
subtraction of the amount of the aptamer remaining in solution after immobilisation 
(including the aptamer found in the washing fractions) from the amount of aptamer in 
the original solution. Aptamer concentrations were determined with a NanoDrop
TM
 
1000 spectrophotometer utilising the respective buffer as a blank. The concentrations 
were calculated based on the Lambert–Beer equation utilising the corresponding 
extinction coefficient. 
6.1.15 Activation of aptamers via cyanuric chloride  
Amino-modified aptamers were activated for coupling to other amino groups by using 
cyanuric chloride (22). 100 µl of the aptamer (200 µM in H2O) were mixed with 80 µl 
of freshly prepared SBB buffer 0.1 M, pH 8.3. Cyanuric chloride was freshly solved in 
acetonitril (HPLC grade) at a concentration of 20 mg/ml. 10 µL of the cyanuric chloride 
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solution were added to the 180 µl aptamer solution, mixed and incubated for 1 h at room 
temperature. Afterwards, the non reacted cyanuric chloride was removed by excessive 
buffer exchange with SBB 0.1 M, pH 8.3 utilising Vivaspin 6 columns with a 3 kDa cut 





6.1.16 Immobilisation of cyanuric chloride-activated aptamers on living cells  
CHO K1 cells were obtained from a shake flask culture, washed once with Dulbecco’s 
PBS and diluted to a concentration of 10
6
 cells/ml. After centrifugation (200 g, 5 min) 
the cell pellet containing 1 million cells was resuspended in 100 µL of the activated 
aptamer (10 µM) in SBB 0.1 M, pH 8.3 and incubated for 15 min under rotation at room 
temperature. Subsequently the cells were centrifuged again and the pellet washed once 
with 500 µl of the respective aptamer binding buffer. The resulting pellet with the 
aptamer modified cells was then used for the flow cytometry assay. 
 
6.1.17 Immobilisation of aptamers on living cells using a biotin-streptavidin 
bridge 
Approximately 3 x 10
6
 cells/ml (CHO) or cultures with OD600 1 (P. pastoris) were used 
for the immobilisation procedure. The cells were taken from shake flask culture and 
washed once with PBS. The cells were then split into reaction tubes in 1 ml portions 
containing 3 x 10
6
 cells/ml and centrifuged at 200 g for 5 min, as in all following wash 
steps. The cell pellets were resuspended in 1 ml NHS Biotin (1 mM) and incubated for 
10 min in a rotator. The cells were subsequently washed once with PBS. Afterwards the 
cell pellets were resuspended in 1 ml streptavidin (50 µg/ml in PBS) and incubated for 5 
min in a rotator. After a washing step with PBS the pellets were resuspended in 200 µl 
of biotinylated aptamer (6 µM in binding buffer) and incubated for 15 min on a rotator. 
The cells were finally washed with the aptamer binding buffer and subsequently used 
for incubation with the target protein (CHO) or for further cultivations (P. pastoris).  
The DNA helix spacer was constructed by hybridisation of the elongated 264 aptamer 
(264 He) and the oligonucleotide-modified biotin (He B). The two partners were mixed 
with a volume of 50 µl each in 264 binding buffer to result in the desired concentration 
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of the aptamer with assembled spacer. The mixture was heated for 3 minutes at 90 °C 
and then left to cool to room temperature for approximately 30 minutes. 
 
6.1.18 Flow cytometry analysis of protein binding to modified beads and 
CHO K1 cells 
The aptamer-modified beads or cells were incubated with 200 µl of the fluorescently 
labelled protein for 30 min in the dark at room temperature while rotating. Afterwards 
the beads or cells are separated from the supernatant using a magnetic separator or a 
centrifuge, respectively. Finally the beads or cells are resuspended in 400 µl aptamer 
binding buffer and analyzed with an Epics XL-MCL flow cytometer (Beckman-Coulter, 
Brea, CA) or an FACS Vantage SE flow cytometer/sorter (BD Bioscience, San Jose, 
CA). At least 10000 events were analyzed per run. The fluorescence intensities resulting 
from the labelled proteins are recorded per event and subsequently analyzed using the 
software WinMDI 2.8. The mean fluorescence intensities are used as values 
corresponding to the amount of protein bound to beads or cells. For analysis signals are 
only taken from living cells by gating the population based on forward and site scatter 
signals in the corresponding dotplot. 
 
6.1.19 Preparation of liposomes / GUVs (giant unilammelar vesicels) by lipid 
film rehydration 
The GUVs were prepared according to a film rehydration protocol by Avanti Polar 
Lipids (133), USA based on Needham et al. (134).  
1. Prepare a lipid stock solution (1 mg/ml) in chloroform:methanol (2:1 v/v) and 
mix the two used lipids (DOPC and DSPE-2000 amine) in a ratio of 50:1.  
2. Place a 50 µl drop of lipid solution using a 50-µl glass syringe onto one side of a 
roughened Teflon disk. Quickly spread the lipid solution over the entire Teflon 
surface using the syringe needle. With the “lipid” side up, place the disk into a 
100-ml beaker. 
3. Remove the volatile organic solvents from the lipid by placing the beaker in 
vacuo for 2 hours. Light sensitive mixtures (as used in this thesis) that contain 
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polyunsaturated lipids should be protected from light using aluminum foil. Purge 
the vacuum with nitrogen gas. 
4. Cover the beaker loosely with Parafilm and prehydrate the lipid film with a 
warm (45-50 °C) water-saturated nitrogen jet for 15 minutes. This was done by 
heating the gas stream in glass pipe system embedded in a waterbath and 
directing it through a wash flask. Pictures of the equipment set up for this 
purpose are shown in Figure 80. 
5. Preheat the buffer (PBS) to be encapsulated at a room temperature. Using a 
disposable plastic syringe fitted with a 0.2 µm syringe filter, gently add the 
rehydration buffer onto the pre-hydrated lipid film. Add enough buffer to 
completely immerse the entire Teflon disk. Seal the beaker with Parafilm to 
prevent water evaporation and incubate overnight at room temperature. 
Typically, vesicles will form after the system is left to swell overnight. 
6. During the incubation period, the lipid film will swell and strip away from the 
Teflon surface to form small “clouds” of vesicles. At this time, vesicles are 
ready for harvest and can be collected by gentle aspiration using a Pasteur 
pipette.  
The pictures below show the equipment, which was set up for the prehydration step by a 
warm and water-saturated nitrogen jet: 
  
Figure 80: A glas flask and a water bath were used to heat up nitrogen and enrich it with water. The jet 
was then directed to the beaker with the Teflon disk to prehydrate the lipids. 
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After harvesting, the vesicles were transferred to an Eppendorf reaction tube and 
concentrated by centrifugation (5 min, 200 g), discarding of the supernatant and 
resuspension of the vesicles in a smaller volume (e.g. 50 µl) of PBS. The vesicles were 
then used for further experiments. 
 
6.1.20 Modification of beads for analysis via Biorad Bioplex 200 and MagPix 
The Beads used for the experiments with the Biorad Bioplex 200 and MagPix 
instruments were prepared according to the following procedure (manufacturers 
instructions, latex beads used for the Bioplex experiments were separated by 
centrifugation instead of magnetic separation) (135): 
1. Bring a fresh aliquot of -20°C EDC powder to room temperature. 
2. Resuspend the amine-substituted oligonucleotide to 1 mM in dH2O. 
3. Resuspend the stock vial of beads by vortexing at speed 7, followed by 
sonication for 15 sec. 
4. Transfer desired volume of the stock beads (based on the scale) to an 
appropriately sized tube (1.5 ml). 
5. Place the tube into a magnetic separator and allow separation to occur for 30-60 
sec. This step is only performed for magnetic beads. The latex beads are 
separated by centrifugation at 5000 g for 5 min. 
6. With the tube still positioned in the magnetic separator, carefully remove the 
supernatant without disturbing the beads. 
7. Remove the tube from the magnetic separator and resuspend the beads in 50 µl 
of 0.1 M MES, pH 4.5, by vortex and sonication for approximately 20 sec. 
8. Prepare a 1:10 dilution of the 1 mM capture oligo to the resuspended beads and 
mix by vortexing. 
9. Add 2 µl (0.2 nmole) of the 1:10 diluted aptamer to the resuspended beads and 
mix by vortexing 
10. Prepare a fresh solution of 10 mg/ml EDC to the beads and mix by vortexing. 
11. Incubate for 30 min at room temperature in the dark. 
12. Add 1.0 ml of 0.02% Tween-20 to the coupled beads. 
13. Use a fresh aliquot of EDC powder to prepare a second fresh solution of 10 
mg/ml EDC in dH2O. 
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14. Add 2.5 µl of fresh 10 mg/ml EDC to the beads and mix by vortexing. 
15.  Incubate for 30 min at room temperature in the dark. 
16. Add 1.0 ml of 0.02% Tween-20 to the coupled beads. 
17. Place the tube into a magnetic separator and allow separation to occur for 30-60 
sec. 
18. With the tube still positioned in the magnetic separator, carefully remove the 
supernatant without disturbing the beads. 
19.  Remove the tube from the magnetic separator and resuspend the coupled beads 
in 1.0 ml of 0.1% SDS by vortex. 
20. Place the tube into a magnetic separator and allow separation to occur for 30-60 
sec. 
21. With the tube still positioned in the magnetic separator, carefully remove the 
supernatant without disturbing the bead pellet. 
22. Remove the tube from the magnetic separator and resuspend the coupled beads 
in 100 µl of aptamer selection buffer, by vortex and sonication for 
approximately 20 sec. 
23. Enumerate the coupled beads by hemacytometer:  
a. Dilute the resuspended coupled beads 1:100 in dH2O. 
b. Mix thoroughly by vortex. 
c. Transfer 10 µl to the hemacytometer. 
d. Count the beads within the 4 large corners of the hemacytometer grid. 
e. Beads/µl = (sum of beads in 4 large corners) x 2.5 x 100  
f. Note: maximum is 50000 beads/µl 
g. Store coupled beads refrigerated at 2-8°C in the dark 
 
For the aptamer sandwich assay, which was analysed with the Biorad MagPix device, 
the aptamer-modified beads were prepared as described above. The sample preparation 
was as follows: 
- 5000 aptamer-modified beads were resuspended in 100 µl VEGF binding buffer 
(TBSE) 
- The beads were separated using a magnetic stand and resuspended in 100 µl 
VEGF with a concentration of 1000 nM 
- The beads were incubated for 30 min at room temperature in a rotator 
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- After separating the beads using a magnetic stand, the beads were resuspended 
in 100 µl of the Cy3-labelled detection aptamer with a concentration of 300 nM 
- After further incubation for 30 min at room temperature in a rotator, 125 µl of 
binding buffer were added and the samples were analysed with the device 
 
6.1.21 Measurement of binding affinity by microscale thermophoresis 
Microscale thermophoresis is a method for determining binding constants based on an 
effect which is called “thermophoresis” and terms the movement of molecules along a 
temperature gradient. The movement depends on changes in size, charge and solvation 
shell of the molecules. Thermophoresis can be detected by fluorescence from either the 
molecule itself (e.g. through tryptophan residues) or fluorescence labels such as FITC, 
that are attached to the molecule. By using titration experiments it is possible to monitor 
the change of movement that is accompanied with increased binding of the interaction 
partners. Affinity constants can be calculated from the resulting data. Figure 81 shows 
the principle of thermophoresis as presented by the company NanoTemper, Munich, 
Germany. 
 
Figure 81: The principal setup and resulting data from a thermophoresis experiment (left). The solution in 
the capillary is heated with an IR-laser which is directed onto the capillary by a mirror. The IR-laser is 
focused on a local spot of the capillary. The fluorescence inside the capillary is detected by a photodiode 
and normalized. The fluorescence value is then plotted against the analysis time (right). After switching 
on the IR-laser, the temperature in the focused area increases, leading to thermophoresis of the molecules. 
This movement is then detected by a decrease of the normalized fluorescence. Binding of molecules to 
each other results in the formation of complexes that migrate slower, which can be detected by MST 
analysis. The obtained data can then be used to calculate binding constants for the interaction. Schematic 
obtained from Seidel et al. (136). 
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The measurements performed with this technique were done to determine the binding 
constant of the anti-IgG aptamer 264. The results are shown in 4.2.1.2. The experiments 
were conducted with a constant concentration of 100 nM of the FITC labeled 264 
aptamer and a concentration series of the Fc-fragment. The highest concentration of IgG 
was 5 µM, from which 15 1:1 dilutions were prepared for the analysis. Tween-20 was 
used with a final concentration of 0.05 % in the analysis buffer to prevent adherence at 
the capillary walls of the device. The measurements with the aptamer 264 and the 
polyclonal human IgG were performed using the device for label free analysis. In this 
case the IgG concentration was kept constant at 500 nM and a concentration series of 
the aptamer 264 was prepared. The highest concentration used was 50 µM from which 
1:1 dilutions were prepared. The samples were also prepared with a final concentration 




Table 5: Overview of used chemicals. 
Substance Supplier, country 
Acetonitril (HPLC-Grade) VWR International, LLC, 
Germany 
Cyanuric chloride Fluka (Sigma-Aldrich), USA 
Dimethylsulfoxid (DMSO) Carl Roth GmbH & Co.KG 
EDC Sigma-Aldrich, USA 
EDTA-Disodium salt Fluka (Sigma-Aldrich), USA 
Ethanol  VWR International, LLC, 
Deutschland 
FITC-conjugated ChromPure Human IgG, Fc Fragment Jackson ImmunoResearch 
Laboratories, Inc, USA 
Glycerin AppliChem GmbH, Germany 
Glycin Fluka (Sigma-Aldrich), USA 
HCl, concentrated Fluka (Sigma-Aldrich), USA 
IPTG Sigma-Aldrich, USA 
Magnesiumsulfat  Fluka (Sigma-Aldrich), USA 
Mangansulfat  Fluka (Sigma-Aldrich), USA 
Methanol (HPLC-Grade) Carl Roth GmbH & Co.KG 
NHS-FITC Sigma-Aldrich, USA 
Peptone Biotechnica internacional S.A. 
DE C.V., Mexiko 
Potassiumchloride Fluka (Sigma-Aldrich), USA 
Potassiumdihydrogenphosphate Merck KGaA, Deutschland 
Sodiumchloride Merck KGaA, Germany 
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Sodiumhydroxide  Fluka (Sigma-Aldrich), USA 
Sodiumphosphate  Fluka (Sigma-Aldrich), USA 
Streptavidin-FITC Sigma-Aldrich, USA 
Yeast Nitrogen Base (YNB) Fluka (Sigma-Aldrich), USA 
Yeastextract Carl Roth GmbH & Co.KG 
 
6.2.2 Disposables 
Centrifugal concentrators, Vivaspin 6 (3 kDa cut off), Sartorius Stedim Biotech, 
Germany 
Centrifuge tubes, 15 ml and 50 ml, Sarstedt AG & Co., Nümbrecht, Germany 
Erlenmeyer flasks, 125 ml, 250 ml, VWR International GmbH, Darmstadt 
Reaction tubes, Sarstedt AG & Co., Nümbrecht, Germany 
Sterile filters, Minisart 0,2 µm, Sartorius Stedim Biotech, Germany 
Syringes, Omnifix, Braun, Germany 
T-Flasks, 25 and 75 cm
2
, Sarstedt Teruma Europe NV, Leuven 
Halbmikroküvette, Sarstedt AG & Co., Nümbrecht 




Spectrophotometer, Nano Drop ND-1000 NanoDrop Technologies, Inc., Wilmington, De, 
USA 
Spectrofluorometer, Nano Drop ND-3300 NanoDrop Technologies, Inc., Wilmington, De, 
USA 
Microarray scanner: GenePix®4000B  Axon Instruments, USA 
Incubator, Heracell 240 Heraeus Holding GmbH, Hanau, Germany 
Cedex cell counter Innovatis, Roche GmbH, Germany 
Arium 611, Ultrapure Water System Sartorius Stedim Biotech, Germany 
Microarray spotter: NanoPlotter 2.1 GeSiM 
Shaker  IKA Werke GmbH, Staufen 
Centrifuge, Multifuge 3 s, Megafuge 1.0 RS Heraeus Holding GmbH, Hanau 
Balance, Analytik AC 210S Sartorius Stedim Biotech, Germany 
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Centrifuge, Eppendorf 5415C Eppendorf AG, Germany 
Fluorescence microscope, Olympus IX 50 Olympus Corporation, Tokio, Japan 
FPLC, BioLogic Duo-Flow Systems Bio-Rad, München 
Autoclave, Systec V-150 Systec GmbH, Wettenberg 
Cell sorter, FACS Vantage SE 
Software Cell Quest Pro v 3.5 
Laser: Coherent Enterprise II, Argon Ion (488 nm) 
Filters: FL1: 515-545 nm; FL2: 564-606 nm;  FL2: 
665-685 nm 
BD Biosciences, Heidelberg, Germany 
Flow cytometer, Epics XL-MCL 
Software WinMDI 2.8 
Laser: Argon Ion (488 nm) 
Filters: FL1: 505-545 nm; FL2: 560-590 nm;  FL3: 
660-690 nm 
Beckman Coulter, Krefeld, Germany 
Electrophoresis system Thermo Fisher Scientific, Bonn, Germany 
Gel documentation, Gel IX Imager Intas Science Imaging Instruments GmbH, 
Göttingen, Germany 
Microplate Reader, Epoch BioTek Instruments Inc., VT, USA 
Shaker Rotator Bio-RS-24,  Peqlab, Erlangen, Germany 
Magnetic stand - Dynamag-2 Life Technologies, Darmstadt, Germany 
YSI 2700 Select Analyzer 
 
YSI Inc. Life Scieces, Yellow Springs, USA 
 
 
6.2.4 Buffer compositions 
Phosphate buffered saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 , KH2PO4, pH 7.4 
 
TD05 Binding buffer 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 , KH2PO4, 5mM MgCl2, pH 7.4 
(137) 
 
264 Binding buffer 
20 mM Tris HCl, 150 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.3 
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Lysozyme aptamer binding buffer 
MgCl2 buffer: 10 mM Tris-HCl, 5 mM MgCl2, pH 7.5 (128) 
 
VEGF aptamer binding buffer (TBSE) 
10 mM Tris-HCl, 100 mM NaCl, 0,05 mM EDTA, 50 mM KCl, pH 7.0 (123) 
 
6.2.5 Aptamers and oligonucleotides 
Aptamers and oligonucleotides for negative controls were ordered from Biospring 
GmbH, Germany, or from IDT Inc., USA and stored according to manufacturers 
recommendations. 
TD05 aptamer (137) 
5‘ AAC ACC GGG AGG ATA GTT CGG TGG CTG TTC AGG GTC TCC TCC CGG 
TG 3‘ 
 
Random oligonucleotide - 47 bases (R47) - generated using the online tool “Random 
DNA Generator” provided by the Maduro lab at the University of California in 
Riverside (http://www.faculty.ucr.edu/~mmaduro/random.htm - accessed on 
06.06.2011) 
5’ AAA CCG CGT CTC TAC GAC CGG TGC TCG ATT TAA TTT CGC TGA CGT 
GA 3’ 
Pool of random 47mers (Pool)  
Approximately 10
14
 different sequences according to manufacturer. 
 
264 aptamer 
5’TAC GAC TCA CTA TAG GGA TCC TTG CTT ACA TTA CGA CGT ACT GAA 
TTC CCT TTA GTG AGG GTT 3‘ 
 
264 aptamer with elongation for helix spacer formation 
5` T GTG GTC TAT GTC GTC GTT CG TAC GAC TCA CTA TAG GGA TCC TTG 
CTT ACA TTA CGA CGT ACT GAA TTC CCT TTA GTG AGG GTT 3` 
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Biotin oligo for helix spacer formation (98) 
5 -CGA ACG ACG ACA TAG ACC ACA 3` Biotin 
 
Lysozyme aptamer (122,128) 
5’-AGC AGC ACA GAG GTC AGA TGG CAG CTA AGC AGG CGG CTC ACA 
AAA CCA TTC GCA TGC GGC CCT ATG CGT GCT ACC GTG AA-3’ 
 
VEGF aptamers  
V7t1 (124):   
5‘ TGT GGG GGT GGA CGG GCC GGG TAG A 3‘ 
Del5-1 (123): 
5‘ ATA CCA GTC TAT TCA ATT GGG CCC GTC CGT TGG TGG GTG TGC TGG 





1. Statistisches Bundesamt (2012) Sterbestatistik und Lebenserwartung in Deutschland. 
https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefae
lle/AktuellPeriodensterbetafeln.html. 
2. Meyer, M., Scheper, T. and Walter, J.-G. (2013) Aptamers: versatile probes for flow 
cytometry, Appl Microbiol Biotechnol, 97, 7097-7109, 
http://dx.doi.org/10.1007/s00253-013-5070-z. 
3. Roederer, M., Bigos, M., Nozaki, T., Stovel, R.T., Parks, D.R. and Herzenberg, L.A. 
(1995) Heterogeneous calcium flux in peripheral T cell subsets revealed by five-
color flow cytometry using log-ratio circuitry, Cytometry, 21, 187–196. 
4. Chattopadhyay, P.K., Hogerkorp, C.-M. and Roederer, M. (2008) A chromatic 
explosion: the development and future of multiparameter flow cytometry, 
Immunology, 125, 441–449. 
5. Life Technologies Inc. USA 
http://www.lifetechnologies.com/de/de/home/support/tutorials.html. - accessed on 
28.02.2014. 
6. Davidson, B., Dong, H.P., Berner, A. and Risberg, B. (2012) The diagnostic and 
research applications of flow cytometry in cytopathology, Diagn. Cytopathol., 40, 
525–535. 
7. Müller, S. and Bley, T. (2011) High Resolution Microbial Single Cell Analytics. 
Springer-Verlag Berlin Heidelberg, Berlin, Heidelberg. 
8. Czechowska, K., Johnson, D.R. and van der Meer, J.R. (2008) Use of flow 
cytometric methods for single-cell analysis in environmental microbiology, Curr. 
Opin. Microbiol., 11, 205–212. 
9. Preffer, F. and Dombkowski, D. (2009) Advances in complex multiparameter flow 
cytometry technology: Applications in stem cell research, Cytometry B Clin Cytom, 
76, 295–314. 
10. Nurse, P. and Hayles, J. (2011) The cell in an era of systems biology, Cell, 144, 
850–854. 
11. Moretti, P., Behr, L., Walter, J.G., Kasper, C., Stahl, F. and Scheper, T. (2010) 
Characterization and improvement of cell line performance via flow cytometry and 
cell sorting, Eng. Life Sci., NA. 
12. Johnson, K.W., Dooner, M. and Quesenberry, P.J. (2007) Fluorescence activated 
cell sorting: a window on the stem cell, Curr Pharm Biotechnol, 8, 133–139. 
13. Stoltenburg, R., Reinemann, C. and Strehlitz, B. (2007) SELEX--a (r)evolutionary 
method to generate high-affinity nucleic acid ligands, Biomol. Eng., 24, 381–403. 
14. McKeague, M. and Derosa, M.C. (2012) Challenges and opportunities for small 
molecule aptamer development, J Nucleic Acids, 2012, 748913. 
15. Kulbachinskiy, A.V. (2007) Methods for selection of aptamers to protein targets, 
Biochemistry Mosc., 72, 1505–1518. 
References 99 
16. Nitsche, A., Kurth, A., Dunkhorst, A., Pänke, O., Sielaff, H., Junge, W., Muth, D., 
Scheller, F., Stöcklein, W. and Dahmen, C. et al. (2007) One-step selection of 
Vaccinia virus-binding DNA aptamers by MonoLEX, BMC Biotechnol, 7, 48. 
17. Tang, Z., Shangguan, D., Wang, K., Shi, H., Sefah, K., Mallikratchy, P., Chen, 
H.W., Li, Y. and Tan, W. (2007) Selection of Aptamers for Molecular Recognition 
and Characterization of Cancer Cells, Anal. Chem, 79, 4900–4907. 
18. Ellington, A.D. and Szostak, J.W. (1990) In vitro selection of RNA molecules that 
bind specific ligands, Nature, 346, 818–822. 
19. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential 
enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505–
510. 
20. Lübbecke, M., Walter, J.-G., Stahl, F. and Scheper, T. (2012) Aptamers as detection 
molecules on reverse phase protein microarrays for the analysis of cell lysates, Eng. 
Life Sci., 12, 144–151. 
21. Zhu, G., Lübbecke, M., Walter, J.-G., Stahl, F. and Scheper, T. (2011) 
Characterization of Optimal Aptamer-Microarray Binding Chemistry and Spacer 
Design, Chem. Eng. Technol., 34, 2022–2028. 
22. Walter, J.-G., Kökpinar, O., Friehs, K., Stahl, F. and Scheper, T. (2008) Systematic 
investigation of optimal aptamer immobilization for protein-microarray applications, 
Anal. Chem., 80, 7372–7378. 
23. Iliuk, A.B., Hu, L. and Tao, W.A. (2011) Aptamer in Bioanalytical Applications, 
Anal. Chem, 83, 4440–4452. 
24. Davis, K.A., Abrams, B., Lin, Y. and Jayasena, S.D. (1996) Use of a high affinity 
DNA ligand in flow cytometry, Nucleic Acids Res, 24, 702–706. 
25. Davis, K.A., Lin, Y., Abrams, B. and Jayasena, S.D. (1998) Staining of cell surface 
human CD4 with 2'-F-pyrimidine-containing RNA aptamers for flow cytometry, 
Nucleic Acids Res, 26, 3915–3924. 
26. Glaser, V. (2009) Oligo Market Benefits from RNAi Focus, Genetic Engineering & 
Biotechnology News, 29. 
27. Rob Carlson http://www.synthesis.cc/. - accesed on 28.02.2014. 
28. Zhang, P., Zhao, N., Zeng, Z., Chang, C.-C. and Zu, Y. (2010) Combination of an 
Aptamer Probe to CD4 and Antibodies for Multicolored Cell Phenotyping, 
American Journal of Clinical Pathology, 134, 586–593. 
29. Baird, G.S. (2010) Where are all the aptamers?, Am. J. Clin. Pathol., 134, 529–531. 
30. Martino, J.P. (1993) Technological forecasting for decision making. McGraw-Hill, 
New York, London. 
31. Meyer, S., Maufort, J.P., Nie, J., Stewart, R., McIntosh, B.E., Conti, L.R., Ahmad, 
K.M., Soh, H.T. and Thomson, J.A. (2013) Development of an Efficient Targeted 
Cell-SELEX Procedure for DNA Aptamer Reagents, PLoS ONE, 8, e71798. 
32. Ye, M., Hu, J., Peng, M., Liu, J., Liu, J., Liu, H., Zhao, X. and Tan, W. (2012) 
Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine, Int J 
Mol Sci, 13, 3341–3353. 
References 100 
33. Schütze, T., Wilhelm, B., Greiner, N., Braun, H., Peter, F., Mörl, M., Erdmann, 
V.A., Lehrach, H., Konthur, Z. and Menger, M. et al. (2011) Probing the SELEX 
process with next-generation sequencing, PLoS ONE, 6, e29604. 
34. Shamah, S.M., Healy, J.M. and Cload, S.T. (2008) Complex target SELEX, Acc. 
Chem. Res., 41, 130–138. 
35. Yang, M., Jiang, G., Li, W., Qiu, K., Zhang, M., Carter, C.M., Al-Quran, S.Z. and 
Li, Y. (2014) Developing aptamer probes for acute myelogenous leukemia detection 
and surface protein biomarker discovery, J Hematol Oncol, 7, 5. 
36. Morris, K.N., Jensen, K.B., Julin, C.M., Weil, M. and Gold, L. (1998) High affinity 
ligands from in vitro selection: complex targets, Proc. Natl. Acad. Sci. U.S.A., 95, 
2902–2907. 
37. Ulrich, H. and Wrenger, C. (2009) Disease-specific biomarker discovery by 
aptamers, Cytometry, 75, 727–733. 
38. van Simaeys, D., López-Colón, D., Sefah, K., Sutphen, R., Jimenez, E. and Tan, W. 
(2010) Study of the molecular recognition of aptamers selected through ovarian 
cancer cell-SELEX, PLoS ONE, 5, e13770. 
39. Sefah, K., Tang, Z.W., Shangguan, D.H., Chen, H., Lopez-Colon, D., Li, Y., Parekh, 
P., Martin, J., Meng, L. and Phillips, J.A. et al. (2009) Molecular recognition of 
acute myeloid leukemia using aptamers, Leukemia, 23, 235–244. 
40. Mayer, G., Ahmed, M.-S.L., Dolf, A., Endl, E., Knolle, P.A. and Famulok, M. 
(2010) Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures, 
Nat Protoc, 5, 1993–2004. 
41. Raddatz, M.L., Dolf, A., Endl, E., Knolle, P., Famulok, M. and Mayer, G. (2008) 
Enrichment of Cell‐Targeting and Population‐Specific Aptamers by Fluorescence‐
Activated Cell Sorting, Angew. Chem. Int. Ed, 47, 5190–5193. 
42. Avci-Adali, M., Metzger, M., Perle, N., Ziemer, G. and Wendel, H.P. (2010) Pitfalls 
of cell-systematic evolution of ligands by exponential enrichment (SELEX): existing 
dead cells during in vitro selection anticipate the enrichment of specific aptamers, 
Oligonucleotides, 20, 317–323. 
43. Sefah, K., Shangguan, D., Xiong, X., O'Donoghue, M.B. and Tan, W. (2010) 
Development of DNA aptamers using Cell-SELEX, Nat Protoc, 5, 1169–1185. 
44. Shangguan, D., Li, Y., Tang, Z., Cao, Z.C., Chen, H.W., Mallikaratchy, P., Sefah, 
K., Yang, C.J. and Tan, W. (2006) Aptamers evolved from live cells as effective 
molecular probes for cancer study, Proceedings of the National Academy of 
Sciences, 103, 11838–11843. 
45. Hamula, C.L.A., Zhang, H., Guan, L.L., Li, X.-F. and Le, X.C. (2008) Selection of 
Aptamers against Live Bacterial Cells, Anal. Chem, 80, 7812–7819. 
46. Parekh, P., Tang, Z., Turner, P.C., Moyer, R.W. and Tan, W. (2010) Aptamers 
Recognizing Glycosylated Hemagglutinin Expressed on the Surface of Vaccinia 
Virus-Infected Cells, Anal. Chem, 82, 8642–8649. 
47. World Health Organization (WHO) World Cancer Report 2014. 
48. Hicke, B.J., Marion, C., Chang, Y.F., Gould, T., Lynott, C.K., Parma, D., Schmidt, 
P.G. and Warren, S. (2001) Tenascin-C aptamers are generated using tumor cells 
and purified protein, J. Biol. Chem., 276, 48644–48654. 
References 101 
49. Zhao, Z., Xu, L., Shi, X., Tan, W., Fang, X. and Shangguan, D. (2009) Recognition 
of subtype non-small cell lung cancer by DNA aptamers selected from living cells, 
Analyst, 134, 1808. 
50. Kunii, T., Ogura, S.-i., Mie, M. and Kobatake, E. (2011) Selection of DNA aptamers 
recognizing small cell lung cancer using living cell-SELEX, Analyst, 136, 1310. 
51. Chen, C.-H.B., Chernis, G.A., van Hoang, Q. and Landgraf, R. (2003) Inhibition of 
heregulin signaling by an aptamer that preferentially binds to the oligomeric form of 
human epidermal growth factor receptor-3, Proc. Natl. Acad. Sci. U.S.A., 100, 
9226–9231. 
52. Lupold, S.E., Hicke, B.J., Lin, Y. and Coffey, D.S. (2002) Identification and 
characterization of nuclease-stabilized RNA molecules that bind human prostate 
cancer cells via the prostate-specific membrane antigen, Cancer Res., 62, 4029–
4033. 
53. Shangguan, D., Meng, L., Cao, Z.C., Xiao, Z., Fang, X., Li, Y., Cardona, D., Witek, 
R.P., Liu, C. and Tan, W. (2008) Identification of Liver Cancer-Specific Aptamers 
Using Whole Live Cells, Anal. Chem, 80, 721–728. 
54. Ninomiya, K., Kaneda, K., Kawashima, S., Miyachi, Y., Ogino, C. and Shimizu, N. 
(2013) Cell-SELEX based selection and characterization of DNA aptamer 
recognizing human hepatocarcinoma, Bioorg. Med. Chem. Lett., 23, 1797–1802. 
55. Jackman, D.M. and Johnson, B.E. (2005) Small-cell lung cancer, Lancet, 366, 1385–
1396. 
56. Chen, H.W., Medley, C.D., Sefah, K., Shangguan, D., Tang, Z., Meng, L., Smith, 
J.E. and Tan, W. (2008) Molecular Recognition of Small-Cell Lung Cancer Cells 
Using Aptamers, ChemMedChem, 3, 991–1001. 
57. Funakoshi, T., Tachibana, I., Hoshida, Y., Kimura, H., Takeda, Y., Kijima, T., 
Nishino, K., Goto, H., Yoneda, T. and Kumagai, T. et al. (2003) Expression of 
tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its 
contribution to cell motility in small cell lung cancer, Oncogene, 22, 674–687. 
58. Jiménez, E., Sefah, K., López-Colón, D., van Simaeys, D., Chen, H.W., Tockman, 
M.S. and Tan, W. (2012) Generation of lung adenocarcinoma DNA aptamers for 
cancer studies, PLoS ONE, 7, e46222. 
59. Shigdar, S., Lin, J., Yu, Y., Pastuovic, M., Wei, M. and Duan, W. (2011) RNA 
aptamer against a cancer stem cell marker epithelial cell adhesion molecule, Cancer 
Science, 102, 991–998. 
60. Song, Y., Zhu, Z., An, Y., Zhang, W., Zhang, H., Liu, D., Yu, C., Duan, W. and 
Yang, C.J. (2013) Selection of DNA aptamers against epithelial cell adhesion 
molecule for cancer cell imaging and circulating tumor cell capture, Anal. Chem., 
85, 4141–4149. 
61. Zhang, P., Zhao, N., Zeng, Z., Feng, Y., Tung, C.-H., Chang, C.-C. and Zu, Y. 
(2009) Using an RNA aptamer probe for flow cytometry detection of CD30-
expressing lymphoma cells, Lab Invest, 89, 1423–1432. 
62. Li, N., Ebright, J.N., Stovall, G.M., Chen, X., Nguyen, H.H., Singh, A., Syrett, A. 
and Ellington, A.D. (2009) Technical and Biological Issues Relevant to Cell Typing 
with Aptamers, J. Proteome Res, 8, 2438–2448. 
References 102 
63. Hamula, C.L., Zhang, H., Li, F., Wang, Z., Chris Le, X. and Li, X.-F. (2011) 
Selection and analytical applications of aptamers binding microbial pathogens, TrAC 
Trends in Analytical Chemistry, 30, 1587–1597. 
64. Dwivedi, H.P., Smiley, R.D. and Jaykus, L.-A. (2013) Selection of DNA aptamers 
for capture and detection of Salmonella Typhimurium using a whole-cell SELEX 
approach in conjunction with cell sorting, Appl. Microbiol. Biotechnol., 97, 3677–
3686. 
65. Cao, X., Li, S., Chen, L., Ding, H., Xu, H., Huang, Y., Li, J., Liu, N., Cao, W. and 
Zhu, Y. et al. (2009) Combining use of a panel of ssDNA aptamers in the detection 
of Staphylococcus aureus, Nucleic Acids Research, 37, 4621–4628. 
66. Duan, N., Wu, S., Chen, X., Huang, Y. and Wang, Z. (2012) Selection and 
Identification of a DNA Aptamer Targeted to Vibrio parahemolyticus, J. Agric. 
Food Chem, 60, 4034–4038. 
67. Dwivedi, H.P., Smiley, R.D. and Jaykus, L.-A. (2010) Selection and characterization 
of DNA aptamers with binding selectivity to Campylobacter jejuni using whole-cell 
SELEX, Appl Microbiol Biotechnol, 87, 2323–2334. 
68. Tang, Z., Parekh, P., Turner, P., Moyer, R.W. and Tan, W. (2009) Generating 
Aptamers for Recognition of Virus-Infected Cells, Clinical Chemistry, 55, 813–822. 
69. World Health Organization (WHO) (2012) World Health Statistics 2012. 
Noncommunicable diseases: a major health challenge of the 21st century. 
70. Michalet, X., Pinaud, F.F., Bentolila, L.A., Tsay, J.M., Doose, S., Li, J.J., 
Sundaresan, G., Wu, A.M., Gambhir, S.S. and Weiss, S. (2005) Quantum dots for 
live cells, in vivo imaging, and diagnostics, Science, 307, 538–544. 
71. Drummen, G.P. (2010) Quantum Dots—From Synthesis to Applications in 
Biomedicine and Life Sciences, IJMS, 11, 154–163. 
72. http://www.nanocotechnologies.com/Resources/Images/c1740110-6b1b-4dac- bb24-
3c25037fe7d8.gif (20.03.2012). - accessed on 26.03.2012. 
73. http://www.cytodiagnostics.com/fluorescent-nanocrystals.php (26.03.2012). - 
accessed on 26.03.2012. 
74. Chattopadhyay, P.K., Price, D.A., Harper, T.F., Betts, M.R., Yu, J., Gostick, E., 
Perfetto, S.P., Goepfert, P., Koup, R.A. and Rosa, S.C. de et al. (2006) Quantum dot 
semiconductor nanocrystals for immunophenotyping by polychromatic flow 
cytometry, Nat Med, 12, 972–977. 
75. Ibáñez-Peral, R., Bergquist, P.L., Walter, M.R., Gibbs, M., Goldys, E.M. and 
Ferrari, B. (2008) Potential Use of Quantum Dots in Flow Cytometry, IJMS, 9, 
2622–2638. 
76. Watson, A., Wu, X. and Bruchez, M. (2003) Lighting up cells with quantum dots, 
BioTechniques, 34, 296-300, 302-3. 
77. Kang, W.J., Chae, J.R., Cho, Y.L., Lee, J.D. and Kim, S. (2009) Multiplex Imaging 
of Single Tumor Cells Using Quantum-Dot-Conjugated Aptamers, Small, 5, 2519–
2522. 
78. Li, Z., Huang, P., He, R., Lin, J., Yang, S., Zhang, X., Ren, Q. and Cui, D. (2010) 
Aptamer-conjugated dendrimer-modified quantum dots for cancer cell targeting and 
imaging, Materials Letters, 64, 375–378. 
References 103 
79. Mazumder, S., Dey, R., Mitra, M.K., Mukherjee, S. and Das, G.C. (2009) Review: 
Biofunctionalized Quantum Dots in Biology and Medicine, Journal of 
Nanomaterials, 2009, 1–17. 
80. Bagalkot, V., Zhang, L., Levy-Nissenbaum, E., Jon, S., Kantoff, P.W., Langer, R. 
and Farokhzad, O.C. (2007) Quantum Dot−Aptamer Conjugates for Synchronous 
Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence 
Resonance Energy Transfer, Nano Lett, 7, 3065–3070. 
81. Chu, T.C., Shieh, F., Lavery, L.A., Levy, M., Richards-Kortum, R., Korgel, B.A. 
and Ellington, A.D. (2006) Labeling tumor cells with fluorescent nanocrystal–
aptamer bioconjugates, Biosensors and Bioelectronics, 21, 1859–1866. 
82. Zhang, J., Jia, X., Lv, X.-J., Deng, Y.-L. and Xie, H.-Y. (2010) Fluorescent quantum 
dot-labeled aptamer bioprobes specifically targeting mouse liver cancer cells, 
Talanta, 81, 505–509. 
83. Medley, C.D., Bamrungsap, S., Tan, W. and Smith, J.E. (2011) Aptamer-Conjugated 
Nanoparticles for Cancer Cell Detection, Anal. Chem, 83, 727–734. 
84. Duan, N., Wu, S., Yu, Y., Ma, X., Xia, Y., Chen, X., Huang, Y. and Wang, Z. 
(2013) A dual-color flow cytometry protocol for the simultaneous detection of 
Vibrio parahaemolyticus and Salmonella typhimurium using aptamer conjugated 
quantum dots as labels, Anal. Chim. Acta, 804, 151–158. 
85. Dwarakanath, S., Bruno, J.G., Shastry, A., Phillips, T., John, A., Kumar, A. and 
Stephenson, L.D. (2004) Quantum dot-antibody and aptamer conjugates shift 
fluorescence upon binding bacteria, Biochemical and Biophysical Research 
Communications, 325, 739–743. 
86. Wang, T.-y. (2005) Artificially Lipid-anchored Proteins Can Elicit Clustering-
induced Intracellular Signaling Events in Jurkat T-Lymphocytes Independent of 
Lipid Raft Association, Journal of Biological Chemistry, 280, 22839–22846. 
87. Sarkar, D., Vemula, P.K., Zhao, W., Gupta, A., Karnik, R. and Karp, J.M. (2010) 
Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell 
targeting, Biomaterials, 31, 5266–5274. 
88. Elliott, J.T. and Prestwich, G.D. (2000) Maleimide-Functionalized Lipids that 
Anchor Polypeptides to Lipid Bilayers and Membranes, Bioconjugate Chem, 11, 
832–841. 
89. Peterson, B.R. (2005) Synthetic mimics of mammalian cell surface receptors: 
prosthetic molecules that augment living cells, Org. Biomol. Chem, 3, 3607. 
90. Kamitani, R., Niikura, K., Okajima, T., Matsuo, Y. and Ijiro, K. (2009) Design of 
Cell-Surface-Retained Polymers for Artificial Ligand Display, ChemBioChem, 10, 
230–233. 
91. Sarkar, D., Vemula, P.K., Teo, G.S.L., Spelke, D., Karnik, R., Wee, L.Y. and Karp, 
J.M. (2008) Chemical Engineering of Mesenchymal Stem Cells to Induce a Cell 
Rolling Response, Bioconjugate Chem, 19, 2105–2109. 
92. Zhao, W., Teo, G.S.L., Kumar, N. and Karp, J.M. (2010) Chemistry and material 
science at the cell surface, Mater Today (Kidlington), 13, 14–21. 
93. Egger, M., Heyn, S.P. and Gaub, H.E. (1992) Synthetic lipid-anchored receptors 
based on the binding site of a monoclonal antibody, Biochim. Biophys. Acta, 1104, 
45–54. 
References 104 
94. Ko, I.K., Kean, T.J. and Dennis, J.E. (2009) Targeting mesenchymal stem cells to 
activated endothelial cells, Biomaterials, 30, 3702–3710. 
95. Borisenko, G.G., Zaitseva, M.A., Chuvilin, A.N. and Pozmogova, G.E. (2009) DNA 
modification of live cell surface, Nucleic Acids Res., 37, e28. 
96. Zhao, W., Loh, W., Droujinine, I.A., Teo, W., Kumar, N., Schafer, S., Cui, C.H., 
Zhang, L., Sarkar, D. and Karnik, R. et al. (2011) Mimicking the inflammatory cell 
adhesion cascade by nucleic acid aptamer programmed cell-cell interactions, The 
FASEB Journal, 25, 3045–3056. 
97. Tokunaga, T., Kuwahata, K. and Sando, S. (2013) Systematic Exploration of 
Lipophilic Tags That Allow Efficient Anchoring of Aptamers to Live Cell Surfaces, 
Chem. Lett., 42, 127–129. 
98. Zhao, W., Schafer, S., Choi, J., Yamanaka, Y.J., Lombardi, M.L., Bose, S., Carlson, 
A.L., Phillips, J.A., Teo, W. and Droujinine, I.A. et al. (2011) Cell-surface sensors 
for real-time probing of cellular environments, Nature Nanotech, 6, 524–531. 
99. Tokunaga, T., Namiki, S., Yamada, K., Imaishi, T., Nonaka, H., Hirose, K. and 
Sando, S. (2012) Cell surface-anchored fluorescent aptamer sensor enables imaging 
of chemical transmitter dynamics, J. Am. Chem. Soc., 134, 9561–9564. 
100. Mudhar, P. (2006) Biopharmaceuticals: Insight into today's market and a look to 
the future How is the biopharm market shaping up?, Pharmaceutical Technology 
Europe, 18, 20–25. 
101. Lai, T., Yang, Y. and Ng, S.K. (2013) Advances in Mammalian cell line 
development technologies for recombinant protein production, Pharmaceuticals 
(Basel), 6, 579–603. 
102. Wurm, F.M. (2004) Production of recombinant protein therapeutics in cultivated 
mammalian cells, Nat. Biotechnol., 22, 1393–1398. 
103. Backliwal, G., Hildinger, M., Chenuet, S., Wulhfard, S., Jesus, M. de and Wurm, 
F.M. (2008) Rational vector design and multi-pathway modulation of HEK 293E 
cells yield recombinant antibody titers exceeding 1 g/l by transient transfection 
under serum-free conditions, Nucleic Acids Res., 36, e96. 
104. Browne, S.M. and Al-Rubeai, M. (2007) Selection methods for high-producing 
mammalian cell lines, Trends in Biotechnology, 25, 425–432. 
105. Porter, A.J., Racher, A.J., Preziosi, R. and Dickson, A.J. (2010) Strategies for 
selecting recombinant CHO cell lines for cGMP manufacturing: Improving the 
efficiency of cell line generation, Biotechnol Progress, 26, 1455–1464. 
106. Hossler, P. (2012) Protein glycosylation control in Mammalian cell culture: past 
precedents and contemporary prospects, Adv. Biochem. Eng. Biotechnol., 127, 187–
219. 
107. John R. Birch (2011) Protein Expression Technology Review. Improvements in 
Microbial and Mammalian Systems Design Drive Advances in the Filed, Genetic 
Engineering & Biotechnology News, 17. 
108. Du, Z., Mujacic, M., Le, K., Caspary, G., Nunn, H., Heath, C. and Reddy, P. 
(2013) Analysis of heterogeneity and instability of stable mAb-expressing CHO 
cells, Biotechnol Bioproc E, 18, 419–429. 
References 105 
109. Seth, G., Charaniya, S., Wlaschin, K.F. and Hu, W.-S. (2007) In pursuit of a 
super producer-alternative paths to high producing recombinant mammalian cells, 
Curr. Opin. Biotechnol., 18, 557–564. 
110. Kumar, N. and Borth, N. (2012) Flow-cytometry and cell sorting: an efficient 
approach to investigate productivity and cell physiology in mammalian cell 
factories, Methods, 56, 366–374. 
111. Powell, K.T. and Weaver, J.C. (1990) Gel microdroplets and flow cytometry: 
rapid determination of antibody secretion by individual cells within a cell 
population, Biotechnology (N.Y.), 8, 333–337. 
112. Kenney, J.S., Gray, F., Ancel, M.H. and Dunne, J.F. (1995) Production of 
monoclonal antibodies using a secretion capture report web, Biotechnology (N.Y.), 
13, 787–790. 
113. Gray, F., Kenney, J.S. and Dunne, J.F. (1995) Secretion capture and report web: 
use of affinity derivatized agarose microdroplets for the selection of hybridoma 
cells, J. Immunol. Methods, 182, 155–163. 
114. Marder, P., Maciak, R.S., Fouts, R.L., Baker, R.S. and Starling, J.J. (1990) 
Selective cloning of hybridoma cells for enhanced immunoglobulin production 
using flow cytometric cell sorting and automated laser nephelometry, Cytometry, 11, 
498–505. 
115. Brezinsky, S., Chiang, G., Szilvasi, A., Mohan, S., Shapiro, R., MacLean, A., 
Sisk, W. and Thill, G. (2003) A simple method for enriching populations of 
transfected CHO cells for cells of higher specific productivity, Journal of 
Immunological Methods, 277, 141–155. 
116. Pichler, J., Hesse, F., Wieser, M., Kunert, R., Galosy, S.S., Mott, J.E. and Borth, 
N. (2009) A study on the temperature dependency and time course of the cold 
capture antibody secretion assay, Journal of Biotechnology, 141, 80–83. 
117. Manz, R., Assenmacher, M., Pflüger, E., Miltenyi, S. and Radbruch, A. (1995) 
Analysis and sorting of live cells according to secreted molecules, relocated to a 
cell-surface affinity matrix, Proc. Natl. Acad. Sci. U.S.A., 92, 1921–1925. 
118. Holmes, P. and Al-Rubeai, M. (1999) Improved cell line development by a high 
throughput affinity capture surface display technique to select for high secretors, J. 
Immunol. Methods, 230, 141–147. 
119. Borth, N., Zeyda, M., Kunert, R. and Katinger, H. (2000) Efficient selection of 
high-producing subclones during gene amplification of recombinant Chinese 
hamster ovary cells by flow cytometry and cell sorting, Biotechnol. Bioeng., 71, 
266–273. 
120. Zuker, M. (2003) Mfold web server for nucleic acid folding and hybridization 
prediction, Nucleic Acids Res., 31, 3406–3415. 
121. Kelf, T.A., Sreenivasan, V.K.A., Sun, J., Kim, E.J., Goldys, E.M. and Zvyagin, 
A.V. (2010) Non-specific cellular uptake of surface-functionalized quantum dots, 
Nanotechnology, 21, 285105. 
122. Tran, D.T., Janssen, K.P.F., Pollet, J., Lammertyn, E., Anné, J., van Schepdael, 
A. and Lammertyn, J. (2010) Selection and Characterization of DNA Aptamers for 
Egg White Lysozyme, Molecules, 15, 1127–1140. 
References 106 
123. Hasegawa, H., Sode, K. and Ikebukuro, K. (2008) Selection of DNA aptamers 
against VEGF165 using a protein competitor and the aptamer blotting method, 
Biotechnol. Lett., 30, 829–834. 
124. Nonaka, Y., Sode, K. and Ikebukuro, K. (2010) Screening and improvement of 
an anti-VEGF DNA aptamer, Molecules, 15, 215–225. 
125. Miriam Lübbecke (2011) Neue Analyse- und Detektionsmethoden in der 
Microarray-Technologie - Dissertation. 
126. Maria Zahid Production in Pichia pastoris and characterization of genetically 
engineered hepatitis B surface antigen virus-like particles - Dissertation. 
127. Han, D., Hong, J., Kim, H.C., Sung, J.H. and Lee, J.B. (2013) Aptamer-based 
microspheres for highly sensitive protein detection using fluorescently-labeled DNA 
nanostructures, J Nanosci Nanotechnol, 13, 7259–7263. 
128. Han, B., Zhao, C., Yin, J. and Wang, H. (2012) High performance aptamer 
affinity chromatography for single-step selective extraction and screening of basic 
protein lysozyme, Journal of Chromatography B, 903, 112–117. 
129. Long, S.B., Long, M.B., White, R.R. and Sullenger, B.A. (2008) Crystal 
structure of an RNA aptamer bound to thrombin, RNA, 14, 2504–2512. 
130. www.expasy.org/compute_pI. - accessed on 09.09.2013. 
131. Siemeister, G., Schnurr, B., Mohrs, K., Schächtele, C., Marmé, D. and Martiny-
Baron, G. (1996) Expression of biologically active isoforms of the tumor 
angiogenesis factor VEGF in Escherichia coli, Biochem. Biophys. Res. Commun., 
222, 249–255. 
132. Pizarro, S.A., Gunson, J., Field, M.J., Dinges, R., Khoo, S., Dalal, M., Lee, M., 
Kaleas, K.A., Moiseff, K. and Garnick, S. et al. (2010) High-yield expression of 
human vascular endothelial growth factor VEGF(165) in Escherichia coli and 
purification for therapeutic applications, Protein Expr. Purif., 72, 184–193. 
133. https://www.avantilipids.com/index.php?option=com_content&view =article&id 
= 1601&Itemid=382. - accessed on 09.09.2013. 
134. Needham D. and McIntosh T.J., E.E. (1988) Thermomechanical and Transition 
Properties of Dimyristoylphosphatidylcholine/Cholesterol Bilayers, Biochemistry, 
4668–4673. 
135. http://www.bio-rad.com/de-de/product/bio-plex-pro-magnetic-cooh-beads-
related-reagents. - accessed on 22.01.2014. 
136. Seidel, S.A.I., Wienken, C.J., Geissler, S., Jerabek-Willemsen, M., Duhr, S., 
Reiter, A., Trauner, D., Braun, D. and Baaske, P. (2012) Label-free microscale 
thermophoresis discriminates sites and affinity of protein-ligand binding, Angew. 
Chem. Int. Ed. Engl., 51, 10656–10659. 
137. Mallikaratchy, P., Tang, Z., Kwame, S., Meng, L., Shangguan, D. and Tan, W. 
(2007) Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound 
Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells, Molecular & 




 Curriculum Vitae 
 
Personal Data 
Name    Michael Meyer 
Date of birth   24.09.1985  
Place of birth   Hildesheim 
Nationality   German   
     
04/2011 - 05/2014 Doctoral research assistant at the Institute of Technical Chemistry 
Leibniz University Hannover, Supervisor: Prof. Dr. T. Scheper 
Doctoral thesis title: “Applications of aptamers in flow cytometry 
assays” 
 
10/2008 - 03/2011  Master studies (M.Sc.) Life Science, Leibniz University 
Hannover, Final grade: (A) – excellent 
Title of the master thesis: “Identification of off-target drug 
interactions using a novel bioanalytical tool” – research project 
performed at Imperial College London in the group of Prof. Dr. 
David R. Klug, Chemical Biology Center 
 
10/2005 - 09/2008 Bachelor studies (B.Sc.) Life Science, Leibniz University 
Hannover, Final grade: (A) – excellent 
Title of the bachelor thesis: “Bionanoarrays” – Supervisor: Prof. 
Dr. T. Scheper, Institute of Technical Chemistry 
 
Research experience abroad 
04/2010 − 12/2010 Imperial College London  
 Research project and master thesis supervised by Prof. 
David R. Klug; Department of Chemistry - Chemical 
Biology Center 
 
03/2009 − 04/2009 Technion, Israel Institute of Technology in Haifa  
 Research project supervised by Prof. Yuval Shoham, 




2013 Meyer M, Scheper T, Walter J (2013) Aptamers: versatile probes for 
flow cytometry. Appl Microbiol Biotechnol 97:7097-7109. 
2014   M. Meyer, M. Loenne, J.-G. Walter, T. Scheper, „Investigation of 
immobilized Aptamer-Protein Binding by Flow Cytometry“, ACTA 
Manilana. Status: Submitted 
2014   M. Meyer, J.-G. Walter, T. Scheper, „Direct coupling of aptamers on the 
cell surface“, Status: In preparation 
 
Poster 
2013  M. Meyer, J.-G. Walter, T. Scheper, „Aptamer-Quantum Dot Conjugates 
for Bioanalytical Applications“, Dechema Jahrestagung, Frankfurt a.M. 
2013  M. Meyer, M. Loenne, J.-G. Walter, T. Scheper, „Application of 














“Hauptsache geil abliefern! Du musst abliefern, ich muss abliefern, am Ende fragt man 
doch nur, ob du geil abgeliefert hast!“  
Bandleader Gurki aus Heinz Strunks Roman „Fleisch ist mein Gemüse“ 
 
